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Targeting oncogenic miRNAs with Small Molecules for Breast Cancer Therapy 
 
Paloma del C. Monroig-Bosque, B.S. 
 
Advisory Professor: George A. Calin, MD. / Ph.D. 
 
Abstract  
The crucial role of microRNAs (miRNAs) in cancer pathobiology has driven the 
introduction of new drug development approaches such as miRNA inhibition. In order to 
advance miRNA-therapeutics, there is a need to develop screening strategies that can 
target tumors in a specific way. Small molecule inhibitors represent an attractive approach 
to pursue this. However, the absence of molecular structures for most of the miRNAs 
makes it very difficult to predict which inhibitors can bind to them. Herein we designed a 
strategy to screen for small molecules by assesing whether they could directly bind/ 
interact with miR-10b/miR-21. As part of our results, we found a new mechanism of action 
for the multi-tyrosine kinase inhibitor Linifanib (5-6A); it inhibits miR-10b in vitro in breast 
cancer (BC) models. Furthermore, we confirmed that Linifanib (5-6A) interacts with the 
precursor sequence of miR-10b through nuclear magnetic resonance (NMR). Overall, our 
findings demonstrate an effective strategy to screen for small molecule inhibitors of 
miRNAs (SMIRs), one that is applicable for any disease type in which miRNA 
overexpression promotes pathology. More so, we provide a first-in-class lead compound 
for further development in cancer therapeutics. 
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CHAPTER I: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Parts of this section were adapted with permission in part from: Monroig, P et al., 
MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities, 
2013; Monroig, P et al., Small molecule compounds targeting miRNAs for 
cancer therapy, 2015; and Berindan-Neagoe, I and Monroig P et al., 
MicroRNAome genome: A Treasure for Cancer Diagnosis and Therapy 
2014.) 
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Breast Cancer 
 
 
Breast cancer (BC) is the most common non-cutaneous cancer among American 
women, accounting for approximately 1 in every 3 cancers diagnosed. There are more 
than 1,300,000 cases and 450,000 deaths each year worldwide, making BC the second 
leading cause of cancer death in females (exceeded only by lung cancer) [1-3]. The overall 
worldwide burden of BC has doubled from the 1980’s until the present representing an 
enormous threat to women’s health due to the number of patients being constantly 
diagnosed [4]. The vast majority of the cases are seen in women over 40 years of age, 
who have aggressive tumor types or that present at an advanced disease stage [5]. 
 
BC can be categorized under two main subgroups: sarcomas and carcinomas. The 
former, are extremely rare types of histologically heterogeneous cancers that arise from 
connective tissue components within the breast (such as myofibroblasts, lymph or blood 
vessels). The latter, are tumors arising from the breast epithelium that consist on cells that 
line the lobules as well as the ducts.  
 
Carcinomas are the most common type of breast cancer, comprising malignancies 
that are further categorized as either in situ or invasive. Carcinomas in situ are considered 
a premalignant lesions composed of abnormal cells growing in their normal place, at a 
point where they are not yet invading the breast tissue. They are clinically relevant 
because they have been demonstrated to have the potential of progressing and 
transforming into an invasive cancer. It is known that 15-53% of ductal carcinomas in situ 
(DCIS) could become invasive over a period of 10 years if they remain untreated [6]. 
Similarly, lobular carcinoma in situ (LCIS) has been associated with an 8-11 fold increase 
in the relative risk of breast cancer [7]. 
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Invasive carcinomas, on the other hand represent the most aggressive 
presentation of carcinoma, where cancer cells infiltrate the lobules and ducts and begin to 
grow and spread into the breast connective tissue (Figure 1). Once invading the 
surrounding tissue, the tumor can spread to distant body sites such as lymph nodes and 
other organs. The majority of the invasive carcinomas are from ductal origin, accounting 
for approximately 80% of the cases, followed by lobular carcinomas with 10-15% of them 
[8]. The remaining cases are segregated as part of another group, in which they are 
individually characterized by their pathological findings and are known to have different 
prognosis as well as treatment implications. Some of these include tubular, colloid, 
medullary, papillary and micropapillary.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Anatomical localization of invasive breast carcinomas 
 
Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form 
in the lobules or milk glands in the breast. Similarly, ductal carcinoma in situ (DCIS) is a 
non-invasive cancer where abnormal cells surround the lining of the breast milk duct. 
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Molecular and Histological Categorization of BC tumors 
 
 
BC is a clinically heterogeneous disease which is categorized according to 
immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) profile, and is further 
divided into different therapeutic groups based on the presence of estrogen receptor (ER), 
progesterone receptor (PR) and HER2 (also known as ERBB2). More so, the analysis of 
gene expression patterns identified by Perou and colleagues described four signatures: 
luminal, HER2-enriched, basal-like, and normal breast-like subtype [9, 10]. Further along, 
luminal tumors where separated into types A and B. Studies of these patterns have 
demonstrated correlations between patient relapses, clinical outcomes, survival etc [11, 
12]. These characterizations have led researchers to develop gene classifiers such as 
PAM50 (Prediction Analysis of Microarray of 50 genes), which are able to define the major 
intrinsic subtypes to which a tumor belongs to [13].  
 
Recently, the addition of another molecular subtype has been described as 
“claudin low” (CL), in tumors lacking tight junction proteins including claudin 3 and E-
cadherin [14]. Additionally, the proliferation marker Ki-67 was associated with common 
histopathological parameters, but was also another  independent prognostic parameter 
for disease free survival (DFS) and overall survival (OS) in BC patients [15]. Altogether 
these descriptions and most recent findings underlie the importance of molecular and 
histological characterizations in guiding therapeutic approaches as well as prognostic 
predictions for breast cancer patients. 
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BC therapies 
 
 
Over the past decade, we have witnessed a significant progress in early BC 
detection and diagnosis. The favorable outcomes are in their majority attributed to the 
enhancement of mammography screenings, which have reduced breast-cancer related 
deaths by approximately 15-25% [16]. In addition, different therapeutic approaches have 
been effectively used among patients, with surgery being one of the principal methods of 
eliminating localized tumors. Alongside, multiple modalities including conventional 
chemotherapy, molecular targeted therapy and endocrine therapy are being applied 
individually or in combination with surgical approaches to target BC tumors  [17].  
 
Regarding the surgical management of breast cancer, several changes have 
occurred over the past years. Breast conserving therapies, followed by radiation have 
been validated for patients presenting with early tumor stages. These types of surgeries 
are also used in cases of patients with locally advanced tumors, after preoperative 
chemotherapy is given to decrease the tumor size. Sentinel node biopsy and axillary 
lymph node dissection are considered “debatable approaches” with benefits and 
unresolved issues on both. Finally, radical mastectomy remains a valid alternative in 
selected cases [18].  
 
In addition to surgical approaches, targeted therapies have been validated, 
developed and used extensively over the past years in BC patients. The treatment of 
choice for individual patients relies on the molecular markers characteristic of the tumors 
themselves. Tumors with positive ER +/-PR, benefit from adjuvant endocrine therapy and 
chemotherapy. In addition, the HER2 receptor status defines if a patient is subjected to 
Trastuzumab (HER2 positive) or not. In patients with ER and PR negative tumors, 
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chemotherapy is the standard treatment (with Trastuzumab in HER2+ cases). 
Nevertheless patients with TNBC tumors, the treatment guidelines are chemotherapy, 
followed by surgery and lymph node dissection (www.nccn.org).  
 
Even with aggressive, multidisciplinary approaches such as hormone therapy, 
chemotherapy, HER2 targeted therapy and surgery; studies have demonstrated that there 
are an unfortunate 30-50% of patients that relapse after their treatment (regardless of their 
disease stage at the time of diagnosis) [19, 20]. For example, in patients with TNBC, 
studies involving the administration of chemotherapy before surgery suggest that this 
treatment is very effective only in the minority of women with this diagnosis (who have a 
complete pathological response and thus an excellent outcome). In contrast, the outcome 
for the majority of them is relatively poor, due to the presence of residual disease [21].  
Additionally, some of the therapies being used have exhibited serious side effects and 
toxicities [22]. Hence, there is an urgent unmet need to develop novel breakthrough of 
drugs for BC therapy with higher safety profiles and therefore patient compliance and 
therapeutic efficacy. With the aims of developing both local treatment of macroscopic 
tumors and systemic therapies of microscopic disease, current researchers aim to prolong 
the time of remission in patients and decrease the number of metastatic cases. 
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Figure 2: Summary of treatment guidelines for invasive breast carcinoma based on 
receptor status (ww.nccn.org). 
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Non coding RNAs – A shift in the genetic paradigm  
 
 
 
Years ago, researchers constantly emphasized that protein-coding genes were the 
only relevant products of our genetic profile. This principle was propagated to very recent 
times, until ncRNAs were discovered [23]. Today, a more complex view is emerging: 
instead of focusing on genes, we have widened our research to non-coding genomic 
regions that are actually transcribed from what was originally designated as the “junk pile”. 
Furthermore, molecular biology has evolved and redefined dogmatic terms in the field, 
nowadays considering the atomic unit for genetics the RNA transcript (not the gene per 
se).  
 
Important research projects focused on the human genome have been developed 
over the years by scientists all over the world. Most of them have evolved around the 
transcriptome encode by genes in humans. One of the most important studies was 
ENCODE (The Encyclopedia of DNA Elements), which identified functional elements 
demonstrating the fact that RNA can be dually processed yielding both, short and long 
RNAs [24]. Alongside, it demonstrated that even though over 90% of the human genome 
can be transcribed, only about 2% of it actually codifies for proteins [25]. Thus, a vast 
number of transcripts, are non-protein coding RNAs (ncRNAs), that can function in many 
ways, one of which is regulating transcription or translation of protein-coding genes [26, 
27].  
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MicroRNAs  
 
For over ten years, non-coding RNAs (ncRNAs) have been demonstrated to be 
involved in many regulatory mechanisms involving cellular physiological processes and 
other biological ones.[28]. In the early 1990’s the understanding of lin-14, a gene in C. 
elegans by Ambros and colleagues, guided the findings of a type of non-protein coding 
RNA-transcript that negatively regulated translation through an antisense RNA-RNA 
interaction. These elements were later referred to as microRNAs (miRNAs) [29]. However, 
it was not only until the year 2000 that the characterization of a second RNA sequence 
repressing protein expression elucidated the existence of a wider phenomenon 
concerning an unknown genomic regulatory elements: microRNAs (miRNAs) [30].   
 
 
MiRNAs are a type of non-coding RNAs of about 18-22 nucleotides (nt) in length 
which have been validated to regulate genetic expression in a post transcriptional manner. 
They are initially transcribed by RNA polymerase as independent genes, or as introns of 
protein-coding genes [31]. Their widely known for targeting messenger RNAs (mRNAs) 
causing critical changes that can directly inhibit translation, or that can cause mRNA 
instability and therefore degradation. The majority of the protein coding genes 
(approximately 60%), have been proven to be targeted by miRNAs through pairing 
complementarity [32]. 
 
MiRNAs are transcribed from their particular coding gene, as a long primary 
transcript which can fold upon itself further forming a doblue stranded hairpin (pri-
miRNAs). An endonuclease, as well as a microprocessor complex (Drosha and DCGR8) 
cleave the primary transcript forming a precursor sequence of approximately 70 nt in 
length (pre-miRNAs). Proteins such as Exportin 5 and RAN-GTP promote the nuclear 
10 
 
translocation of the precursor sequences into the cytoplasm where another nuclease 
called Dicer further cleaves it. Subsequently, the precursor sequences shortens to a 
double stranded RNA sequence of 18-22 nt in length, which then separates into a guide 
and passenger strand [33]. The guide strand promotes the association of a group of 
proteins reffered to as an RNA-induced silencing complex (RISC) with the complementary 
3’ unstranslated region of the mRNA (s) targeted by the specific miRNA. Even though their 
main function is to target mRNAs, microRNAs have also been known to have many other 
functions, such as regulating promoter regions, targeting cellular receptors, increasing the 
stability of additional mRNAs, influencing cell signaling pathways etc [34]. 
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Figure 3: MicroRNA biogenesis 
MiRNA-coding genes are initially transcribed by an RNA polymerase II or III, creating a 
primary transcript (pri-miRNAs), which can be hundreds or thousands of nt long. It is 
further processed, into a 100 nt precursor transcript. The precursor sequence is then 
exported to the cytoplasm, where it undergoes a series of processing events, prior to 
achieving maturation. Once in the cytoplasm, mature single-stranded miRNAs are 
integrated into a number of proteins that compose the RNA-induced silencing complex 
(RISC), and thereafter they interact by sequence complementarity with the messenger 
RNA (mRNA). In this way miRNAs inhibit translation or alternatively, they can increase 
mRNA instability (consequently causing its degradation). 
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MiRNA functions and role in cancer 
 
The initial link between miRNA levels and cancer development was the miR-15 
and miR-16 dysregulation in B cell CLL, as a result of chromosome 13q14 deletion [35]. 
Further studies have described the fact that many miRNA genes are located in fragile 
genomic sites (regions more susceptible to mutations, rearrangements and loss of 
heterozygosity), which are frequently found in tumorigenesis and cancer development 
[36]. To date, miRNAs have been linked to angiogenesis, uncontrolled proliferation, 
insensitivity to anti-growth signals, and every single one of the cancer hallmarks (Figure 
4) [34]. They do so by tightly regulating tissue processes such as morphogenesis, 
apoptosis, or others [37, 38]. Thus, in this way, the alteration of important messenger 
RNAs (mRNAs) are involved in tumor initiation and progression, as these non-protein 
coding genes behave as oncogenes or tumor suppressor genes [39]. 
 
Tumor suppressive miRNAs reduce the levels expression of oncogenes, and can 
therefore delay carcinogenesis, or disrupt tumor maintenance. They are typically 
downregulated in cancer. On the other hand, oncogenic miRNAs are typically 
overexpressed or amplified in cancer, and they reduce the levels of important tumor 
suppressor proteins. One example of each follows. 
 
MiR-34a has been known as a classic example of a tumor suppressive miRNA. It 
has been shown to be downregulated in several cancer types such as prostete. In prostate 
cancer cells purified from xenograft and primary tumors, its expression was shown to 
inhibit clonogenic expansion, and tumor regeneration as well as the process of metastasis 
because of its targeting of CD44 (a cell- surface glycoprotein involved in cell–cell 
interactions, cell adhesion and migration).  
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A representative example of an oncogenic miRNA is miR-224 in colorectal cancer 
(CRC). MiR-224 expression increases consistently with tumor burden and enhances CRC 
metastasis in vitro and in vivo. SMAD4 was identified as a translational regulator targeted 
by this miRNA as demonstrated in clinical samples. Patients with high miR-224 levels had 
shorter overall survival in multiple CRC cohorts and shorter metastasis-free survival [40].   
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Figure 4: Examples of MicroRNAs Involved in the Cancer Hallmarks.  
This figure is used with permission and originally published by Berindan-Neagoe, I., Monroig, P., Pasculli, 
B., and Calin, G. in 2014 in A Cancer Journal for Clinicians 
(http://onlinelibrary.wiley.com/doi/10.3322/caac.21244/epdf) 
MiRNA-based therapeutic opportunities in cancer 
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Two important strategies have guided the use of these molecules as novel 
therapies. First, miRNA molecules have been modified to achieve a prolonged half-life 
and efficiency in vivo (e.g. anti-miRNA and locked nucleic acid-modified oligonucleotides, 
and antagomiRs). Second, the development of miRNA transgenic mice (such as the miR-
155, and miR17~92) and knockouts (such as miR-15, miR-16, miR-146 and miR-29) have 
offered valuable information that has guided therapeutic opportunities for cancer patients 
[41]. The strategies are based on the following principles: targeting oncogenic miRNAs to 
decrease their levels expression; and restoring tumor suppressive miRNAs to rescue their 
levels expression (Table 1). 
 
i. Inhibiting Oncogenic miRNAs 
Cancer cells contain many genetic and epigenetic abnormalities, but despite their 
complexity, their growth and survival can often be impaired by inactivating a single 
oncogene. This phenomenon, called “oncogene addiction,” provides a rationale for 
molecular targeted therapy [42]. Correlations between regulatory miRNAs and cancer 
have revealed that this concept applies to miRNA dysregulation in patients. Thus, 
regarding the first principle, therapies against oncogenic miRNA focus on decreasing 
miRNA levels by inhibiting them through complementary base pairing. 
 
 Because of the diversity of mechanisms by which miRNA levels contribute to 
tumor initiation and progression, several therapeutic models have been developed to 
target these processes. Therapies to decrease the effect of a specific miRNA have been 
proposed by using antisense oligonucleotides (ASOs) that inhibit targets by adhering to 
the miRNA forming miRNAanti-miRNA binding complexes. Several types have been  
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RNA therapeutic drug Definition  Mechanism of Action 
Antisense oligonucleotides 
(ASOs) 
A single-stranded 
chemically modified DNA-
like molecule 17 to 22 
nucleotides in length 
designed to be 
complementary to a 
selected messenger RNA 
(mRNA). 
Specifically inhibits 
expression of that gene 
mainly through formation of 
an mRNA-ASO duplex by 
sequence complementarity, 
leading to cleavage of the 
mRNA of target gene. 
MicroRNA mimics A microRNA (miRNA) 
mimic is a small single-
strand 19 to 24 nucleotide 
RNA with identical 
sequence to the miRNA of 
interest (to be re-
expressed). 
Mimic the effects of an 
endogenous miRNA with 
consequent inhibition of 
protein production by either 
transcriptional inhibition or 
translational block or both. 
ASOs/AMOs, LNAs, and 
antagomiRs 
The ASOs/AMOs are 
single-stranded, 
chemically modified DNA-
like molecules that are 17 
to 22 nucleotides in length 
and designed to be 
complementary to a 
selected miRNA and 
specifically inhibits its 
expression. The LNAs 
anti-miRNAs represent 
LNA-modified ASOs. The 
antagomirs are single-
stranded 23-nucleotide 
RNA molecules 
complementary to the 
targeted miRNA that have 
been modified to increase 
the stability of the RNA 
and protect it from 
degradation. 
AMOs are ASOs against 
miRNAs, and therefore 
produce ASO-miRNA 
duplex through sequence 
complementarity, leading to 
RNAse-H mediated 
cleavage of the target 
miRNA gene. The LNA 
anti-miRNA have the same 
mechanism as the 
ASO/AMO. The 
miRNA/antagomir-duplexes 
induce degradation of the 
miRNA and recycling of the 
antagomir in a way still not 
completely known.   
Small interfering RNAs 
(siRNAs) 
A double-strand RNA 
homologous to an mRNA 
of a target gene.  
The siRNAs are 
incorporated into a 
multiprotein RNA-induced 
silencing complex, leaving 
the antisense strand to 
guide this complex to its 
homologous mRNA target 
for endonucleolytic 
cleavage of mRNA.   
 
Table 1: Principle Types of RNA-based therapeutic drugs 
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described: antagomiRs, locked nucleic acids (LNAs) and ASOs with chemical alterations 
to optimize efficacy (AMOs) (Table) [43-45]. With the use of antagomiRs, Fontana and 
colleagues demonstrated that tumor growth was inhibited when injecting the antagomiR-
17-p in therapy resistant neuroblastoma cell lines [46]. In reference to the chemically 
modified, Ma and colleagues used AMOs to intravenously inhibit miR-10b in a mammary 
mouse tumor model, and observed that metastasis was inhibited [47]. Park and colleagues 
tested another chemically modified antagomiR, chol-anti-miR-221. In their orthotopic 
mouse model of hepatocellular carcinoma (HCC), they proved that chol-antimiR- 221 
significantly reduced miR-221 levels in the liver, and that this, correlated with a reduction 
in tumor cell proliferation, an increase in apoptosis markers and cell cycle arrest [48]. 
LNA’s, (another type of ASO) have also proven to be efficient, as a liver regeneration 
mouse model tested by Sapra and colleagues demonstrated that using a locked nucleic 
acid antisense oligonucleotide against survivin (an apoptosis inhibitor), reduced its mRNA 
levels in 80%. In addition, researchers have recently engineered a single subunit termed 
“multiple-target anti-miRNA antisense oligodeoxyribonucleotide” (MTg-AMO), through 
which simultaneous silencing has been achieved [49]. MTg-AMO’s have been proven to 
allow the restoration of dysregulated miRNA levels by targeting several key aspects of the 
biology of cancer cells in tumor tissue at once. For example, Lu and colleagues 
demonstrated that the MTg-AMO targeting miR-155 and miR-17-5p produced a greater 
inhibitory effect on cancer cell growth, compared with the regular single-target AMOs [50]. 
 
Another therapeutic approach to decrease miRNA levels involves expressing 
competitive inhibitors of their function. The typical example are “microRNA sponges” which 
are vectors containing multiple artificial miRNA binding sites that are placed under the 
control of strong promoters to produce large quantities of transcript [51]. These transcripts 
express multiple tandem sites to a miRNA of interest [52]. MiRNA sponges were used in 
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metastatic breast cancer mouse model, where in vivo experiments demonstrated that the 
downregulation of an over-expressed breast cancer miRNA (miR-19) could be achieved, 
along with metastasis inhibition [53].  
 
ii. Restoring tumor suppressive miRNAs 
Although miRNAs are mostly known to be overexpressed in cancer tissue, they can 
also be downregulated in tumors [54]. This fact recalls the second principle mentioned 
above (regarding miRNA-therapeutics): restoring the levels of tumor suppressive miRNAs. 
In the past, global repression of miRNA expression has been proven to increase 
tumorigenesis in both in vitro and in vivo models [55]. For tumors with reduced expression 
of miRNAs, restoring their basal levels is the key strategy, which can be achieved through 
miRNA mimetics, which are synthetic small RNAs that contain the exact sequence of the 
endogenous ones. To achieve the delivery of a stable molecule, miRNA’s are delivered 
as perfectly complementary duplexes, similar in architecture to siRNAs [56]. 
 
The majority of the therapies that have tried to restore tumor suppressive miRNA 
with mimetics have achieved their goal by administering them locally. However, nowadays 
the challenge of developing a systemic delivery in a tissue/cell-type specific manner has 
been proven to be achievable through different delivery systems. The lead candidate in 
this field has been MRX34 from Mirna Therapeutics [57]. The liposome-encapsulated miR-
34 mimic for patients with unresectable primary liver cancer has evolved into a (currently 
open) clinical trial. It is a phase I, open-label, multicenter dose-escalation study to 
investigate the safety, pharmacokinetics and pharmacodynamics of the MRX34 
(ClinicalTrials.gov Identifier: NCT01829971). 
Oncogenic miRNAs miR-21 and miR-10b, and their role in BC 
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Over the past years, the molecular mechanisms that underlie breast cancer 
pathogenesis gave been extensively researched. However many challenges prevail when 
managing patients. Some of these include: relapses, resistance to known treatments, and 
metastasis. As regulators of tumor suppressor protein-coding genes, miRNAs where 
thought to be attractive oncogenic agents to target in BC therapeutics. In the year 2005, 
miRNA dysregulation was associated with BC for the first time [58].  Since then, many 
studies have identified aberrantly expressed / clinically relevant miRNAs [59-62]. Two 
examples of these are miR-10b and miR-21. 
 
MiR-10b has been demonstrated to initiate tumor invasion and metastasis by positively 
regulating cell migration and invasion in BC [63, 64]. It does so by indirectly causing the 
activation of the pro-metastatic gene RHOC through suppression of HOXD10. HOXD10 
is a transcriptional repressor involved in cellular migration and extracellular modelling 
(such as RhoC, uPAR, α3-integrin and MT1-MMP) [65]. Furthermore, miR-10b has been 
shown to be therapeutically relevant in mouse mammary tumor models, where its silencing 
inhibited metastasis development [47]. Its clinical relevance has been seen in patient 
samples, where miR-10b expression levels are lower in all of the breast carcinomas from 
metastasis-free patients; but in contrast, the majority of metastasis-positive patients have 
elevated miR-10b levels in their primary tumors [66]. This effect has been demonstrated 
to be independent of the tumor subtype. Notably, overexpression of miR-10b in otherwise 
non-metastatic breast cancer cells confers invasive and metastatic abilities on these cells 
when they are growing (as proven in xenografts in vivo) [66]. Overall these facts thoroughly 
exalt the importance of targeting miR-10b in BC therapeutics. 
On the other hand, miR-21 has been found consistently upregulated in BC 
carcinoma in situ compared to normal tissue [67]. In patients, levels of serum miR-21 has 
been found to be significantly higher compared to controls, suggesting its usage as marker 
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for early stage BC detection [68]. Its overexpression has been correlated with specific BC 
bio-pathologic features such as advanced tumor stage, lymph node metastasis and also 
with poor patient survival [69]. Several tumor suppressor proteins have been validated as 
targeted by miR-21; some of these include TIMP3, ANKRD46, TPM1, PDCD4 and Maspin 
[70-72]. Knockdown of miR-21 in BC cells has been demonstrated to inhibit migration in 
vitro as well as growth in vitro and in vivo [71]. Therefore, the finidngs to this date also 
suggest that miR-21 is another attractive miRNA to target in BC. 
 
Interestingly, both miRNAs -10b and -21 have been identified as promoters of 
metastatis progression (Figure 4) [72] .Thus, the discovery of a therapeutic agent that 
could directly interact with miR-10b/miR-21 would open a new window of treatment 
opportunities to explore against cancer; both, as a single agent or in combinatorial 
therapies.   
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Figure 5: MiRNAs -10b and -21 are involved in metastasis progression in BC 
patients.  
This figure was adapted and used with permission (and originally published by) Pencheva, N. 
Tavazoie, S. F. Nature cell biology 2013 
(http://www.nature.com/ncb/journal/v15/n6/full/ncb2769.html) 
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Delivery Mechanisms 
 
The main focus of miRNA-therapeutics is to be able to deliver the agents in vivo 
(both locally and systemically). Local approaches such as direct site injection have several 
evident advantages. Some of these are evasion of nuclease degradation, decrease uptake 
by non-targeted tissues, and increase bioavailability at the tumor targeted site. 
Nevertheless they are applicable to a limited number of tissues such as ocular and brain 
[73]; and even in these tissues, not all targeted tumor cells are reached by the miRNA-
therapeutic agents [74]. On the other hand, a systemic delivery consisting of a 
bloodstream injection, theoretically should achieve a more efficient delivery to targeted 
sites. Neverrtheless, this mechanisms have to overcome several barriers (in vivo) such as 
nuclease degradation and non-specific targeting of tissues that are reached by blood 
vessels nearby (eg. liver, jejunum, kidney) [74].  
 
As an approach to surpass some of these obstacles, changes such as chemical 
modifications, encapsulations and conjugations have aimed to protect miRNA-based 
therapeutic agents so they can be stably conserved while in the bloodstream (where they 
are required to maintain intact). In this way, they are able to traverse cellular membranes 
and more importantly reach the cytosol, where they perform their main function [75]. Thus, 
overall, the development of efficient carriers remains a challenge since synthesizing a 
stable, biodegradable and biocompatible miRNA-therapeutic agent is important, but 
ensuring an adequate cell penetration and molecular delivery is also crucial.  
 
Current known carriers can be separated into 2 groups: viral and non-viral. Both 
groups target tumor tissues and aim to evade immunological reactions / (cause toxicity). 
Viral-based strategies have been used in the past with vectors such as lentivirus, 
23 
 
adenoviruses and adenoassociated virus (AAVs), and through specific genetic 
manipulation they have been able to target the tissues of choice [76, 77]. However, even 
though preclinical in vivo models (using virus as vector-mediated delivery) have shown 
promising results, they continue to present flaws that need to be addressed before 
advancing into the clinic (such as undesired immunogenic responses) [75]. 
 
Non-viral strategies, such as liposomes, have been thoroughly used and have 
proved to induce tumor suppression in vivo [78-80]. Their success has been accomplished 
due to the evasion of the oligonucleotides from being degraded by nucleases, and due to 
their ability to increase the circulating half-life when systemically delivered [73]. 
Nevertheless, some of these systems have had adverse effects in vivo, mostly related to 
the positive charge of the lipid component (which also triggers undesired immune 
responses) [73, 81]. 
 
A strategy that has begun to overcome these toxic effects has been the 
development of neutrally charged liposomes, based on 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) [82]. In this way, nanoliposomes deliver microRNA-based 
therapeutic agents into tumor cells much more efficiently in vivo. Several studies have 
proven that this approach is effective. For example, in a mouse model for lung cancer, 
Trang and colleagues systemically delivered the tumor suppressor miR-34a in a neutral 
lipid emulsion and obtained a 60% reduction in tumor area compared to controls [83]. In 
an additional model, mice with ovarian cancer tumors were treated with neutral-DOPC 
liposomes thich incorporated siRNA to target the oncogene EphA2. Through their 
experiments Landen and colleagues demonstarated that they could efficiently achieve a 
reduction in tumor growth (compared to control) [84]. Interestingly, another approach 
includes coating cationic bilayers with polyethylene glycol (PEG), demonstrated 
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effectiveness and safety by decreasing immunogenic responses [85]. Finally the addition 
of biodegradable synthetic or natural polymers could also represent an effective 
alternative to facilitate sustained delivery in vivo, although once again, toxicity remains a 
continuos challenge. Overall, the findings described above are still under development 
and have not yet reached their primary endpoint completely. More so, the fact of having 
to produce a delivery agent to administer therapy will continue to remain a burden, and 
are consuming both: time and money.  
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Small Molecule compounds targeting miRNAs for cancer therapy 
 
 
 
Drug discovery and development are extremely long processes that take 
approximately 10–15 years. In addition, drug production results in an incredible economic 
burden that “boosts” their final overall cost, and patients end up having to pay exaggerated 
prices for their treatments. Thus, time and cost are considered the main obstacles in 
achieving new therapeutic alternatives for cancer treatment. Nonetheless, over the years, 
the study of different types of proteins as well as other types of molecules, has led to the 
discovery and identification of many inhibitors that are currently being used in the clinic. 
More so, several therapeutic approaches using miRNAs have also begun to be developed. 
However, even know some miRNA-based therapeutic strategies have been truly exciting, 
there are challenges involved in the delivery of these non-small-molecule agents, and 
even more, their pharmacodynamic and pharmacokinetic properties are not ideal for 
clinical application [73, 81]. For this reason, there is still a need of developing new 
alternative therapeutic approaches to inhibit oncomiRs, and decrease their activity. 
 
Over the past years, significant attention has been focused on overexpressed 
oncomiRs, and several studies have been published regarding the initiation and 
development of a novel therapeutic approach for miRNA inhibition: the use of small 
molecule inhibitors (Figure 6). Small molecules have been thoroughly used with clinical 
applications for numerous diseases, but also specifically for cancer [86, 87]. The use of 
chemical compounds that are already FDA approved to treat a specific disease (“X”), 
would accelerate the process of completing toxicological studies and clinical trials in order 
to apply it to another disease (“Y”). If a compound has already been through thorough pre-
clinical testing and FDA-related studies (10 or more years), then using the exact 
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compound for another disease would eliminate the need of going through the process 
again (shortening both money expenses and time consuming processes).  
 
On the other hand, small molecule compounds could facilitate the identification of 
specific motifs from a lead compound. Then, by modifying the known compound rather 
that designing a new one (“from scratch”), researchers could also decrease the time it 
takes to synthesize and test a molecule de novo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Small molecule compounds targeting microRNAs 
This figure is used with permission and originally published by Monroig, P., Chen, L., Zhang, S., and Calin, 
G. in 2015 in Advanced Drug Delivery Reviews 
(http://www.sciencedirect.com/science/article/pii/S0169409X14002002) 
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i. A novel approach with new challenges  
The interaction of small molecules and miRNAs was termed for the first time as 
“SMIR” by Melo, Calin, and colleagues [88, 89], referring to small molecules inhibitors of 
RNAs. The novel concept represented an attractive modality to eventually develop more 
targeted cancer therapies. The idea of targeting RNAs, (in our case miRNAs specifically) 
with small molecules seems very convenient in the sense that it is considered to be a way 
of selecting a “fast-track pathway” in the drug developing race, reducing the time it takes 
to develop, produce and approve drugs, not to mention the manufacturing (and overall) 
cost of the process. If successful, targeting miRNAs with small molecules from which pre-
clinical / clinical trials have previously been perfomed, could definitely result in an effective 
drug, reaching the patient's bedside in an incredibly short period of time.  
 
Although interesting, the idea behind targeting miRNAs with small molecules 
involves embracing many risks and challenges. For example, compared to proteins, RNA 
transcripts have never before been considered drug targets due to their electronegativity 
and structural flexibility. More so, the absence of molecular structures of the majority of 
the miRNAs, as well as the limited availability of miRNA-Dicer or RISC complex structures 
makes their discovery increasingly difficult [90]. Nonetheless, recent findings suggest that 
indeed miRNAs are good genetic elements to target [88]. The secondary structures of 
immature miRNA transcripts, specifically in the pre-miRs, actually form stem loops and 
bulges that facilitate their targeting by small molecule inhibitors. Thus, in this way, they 
represent attractive “druggable” elements [91].  
 
ii. Developing a new concept 
A few years ago, Deiters and colleagues described that there are 3 basic 
processing stages which miRNAs require in order to perform their main function. More 
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so, they envisioned that small molecules could indeed block miRNA maturation at all 
3 of them: pre-transcriptionally, at the level of transcription, or post-transcriptionally 
[92]. They determined that several ideas were possible; herein we briefly discuss them. 
 
First of all, they perceived that pre-transcriptionally, small molecules could 
decrease the levels of miRNA expression as well as their function [92]. By altering miRNA 
promoter regions, small molecules where speculated to regulate miRNA expression in an 
indirect way. Also, small molecules were thought to potentially inhibit deacetylation or 
promote hypermethylation and thereby decrease the expression of miRNA-coding genes 
[93, 94].  
 
Secondly (but in a similar way), transcription factors were also thought as plausible 
elements to be targeted by small molecules. By inhibiting their function, small molecules 
could (in a way) decrease or inhibit completely the expression of genes coding for 
miRNAs. For example, c-Myc has been demonstrated to activate the expression of 2 
miRNAs from a cluster: miR-17-5p and miR-20a. Both of these are known to negatively 
regulate the expression of E2F1, thereby promoting G1-to-S phase progression [95]. 
Thus, the idea behind this rationale was that a small molecule could target oncogenic 
transcription factors such as E2F1, and in this way inhibit the expression of oncogenic 
miRNAs (miR-17-5p and miR-20a) resulting in recovery of tumor suppressor proteins.  
 
Thirdly, small molecules were also speculated to target the process of miRNA 
biogenesis (post-transcriptionally), by inhibiting RNA-endonucleases (e.g. Drosha/Dicer), 
or other important proteins [96-99]. These crucial elements, (required to produce mature 
miRNA sequences), were thought to be potential targets to inhibit with small molecule 
compounds in order to decrease the expression of oncogenic miRNAs.   
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Overall, by comparing the different steps of miRNA regulation, research groups 
speculated that targeting transcription was the most effective way of inhibiting miRNAs 
[92]. However, the truth of the matter was that after different screenings were completed, 
it was clear that targeting transcription factors was not a way of targeting miRNA 
expression in a specific way. The rationale behind it is that transcription factors can 
ubiquitously affect promoter regions of many genes simultaneously, including oncomiRs, 
tumor suppressor miRs or genes coding for miRNAs that regulate cellular homeostasis. 
 
Nowadays, after developing a deeper understanding of the field, the main goal of 
the SMIR-based approach, is to discover compounds that can potently bind, and decrease 
the levels of miRNAs in the most specific way possible [100]. The aim is for a small 
molecule, to target a mature miRNA sequence by binding to it, or any of its upstream 
precursors. If a small molecule inhibitor could be proven to bind to any of these sequences 
directly, it could be used in any cancer type (or even disease) that overexpresses that 
specific oncogenic miRNA. In order to achieve this, the initial step is determining which 
miRNAs are important oncogenic targets. Following this, an efficient screening technique 
needs to be developed and validated, in order to search for small molecule compounds 
from chemical libraries. 
 
iii. Screening techniques to identify SMIRs  
Screening chemical compound libraries is a drug-discovery approach broadly used 
in research for many types of studies. The process usually involves “quick” methods to 
assess the biological or biochemical activity of numerous compounds, in the shortest 
amount of time with the highest precision possible. The identification of hit compounds 
through screening techniques tipically provides a basis/starting point for future drug 
design. Screening techniques have been used previously by several research groups in 
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order to identify small molecule inhibitors of miRNAs [101-103]. The initial SMIR-screening 
approaches can be done either in vitro or in silico; and both of these types of techniques 
have been recently explored [103-109]. Herein we describe several assays used in vitro. 
For a summary of in silico approaches to target SMIRs please refer to [100].  
 
Assays detecting fluorescence  
An example of an assay using fluorescence to detect changes in 
miRNA levels are fluorescent beacons. These are oligonucleotide 
hybridization probes that can report the presence or the absence of specific 
nucleic acids (such as miRNAs) in solutions. They are hairpin shaped 
molecules, composed of a quencher, as well as a fluorophore that can emit 
fluorescence when interacting to its complementary target sequence. The 
technique has been proven useful in past research studies [106, 107]. It is 
performed by synthesizing a doubly-labeled precursor beacon containing a 
5′ fluorescence emitter, and a 3′ quencher. Dicer-mediated hydrolysis of 
the precursor results in a dissociation of the fluorescence emitter and 
quencher, generating a Dicer-dependent increase in the fluorescence. If a 
small molecule is not effective in inhibiting the miRNA, the miRNA itself 
would bind its complementary sequence in the beacon and fluorescence 
emission would be high. On the other hand, an effective SMIR would not 
allow the miRNA to bind the beacon, therefore there would be less 
fluorescence (Figure 7A). 
 
Alternatively, another research group developed a DNA molecular 
beacon that is independent of the precursor sequence and complementary 
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to the mature miRNA produced after the Dicer cleavage (and in this way 
Dicer cleavage is not expected to be altered in any way) [103].  .  
 
Luciferase reporter constructs  
Luciferase biosensors assays are an efficient / rapid screening 
technique to determine the levels of miRNAs in vitro. These vectors are 
usually assembled by introducing the complementary sequence of the 
miRNA of interest. An additional vector with a control sequence, 
downstream of a luciferase reporter gene is used alongside (to blank 
artifact effect). The reporter constructs are then used as sensors to 
determine the presence of specific mature miRNAs. The plasmids are 
cloned and further sequenced, validated, and transfected into cells. The 
system has been tested and proved efficient in detecting minor changes in 
endogenous miRNA levels. The basis of the assay is as follows: in the 
presence of a SMIR that efficiently targets the miRNA of interest, the 
mature sequence is decreased, and the luciferase gene is expressed 
constitutively. If the compounds tested do not inhibit the miRNA, then the 
miRNA will bind to its target sequence and inhibit the expression of the 
luciferase gene. Herein we briefly describe 2 examples. 
 
 
 
 pEZX-MT05 plasmid  
The pEZX-MT05 vector from (GeneCopoeia) also offers the 
opportunity of miRNA target identification. Similarly, miRNA 
complementary 3′ UTR sequences are inserted downstream of the 
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secreted Gaussia luciferase (GLuc) reporter gene in its respective vector 
system, driven by SV40 promoter for expression in. Besides using GLuc as 
the miRNA 3′ UTR target reporter, a secreted Alkaline Phosphatase 
(SEAP) reporter driven by a CMV promoter, is also cloned and it serves as 
the internal control. In addition to the GLuc/SEAP dualreporter vector 
system, a firefly/Renilla Duo-Luciferase reporter vector (pEZX-MT01) has 
also been validated and is currently available for SMIR screening [108]. 
 
  psiCHECK-2 reporter plasmid  
The psiCHECK2 vector (Promega) has been a useful tool to screen for 
SMIRs in vitro. It is a reporter plasmid in which researchers clone a miRNA 
target sequence downstream of a Renilla luciferase (Rluc) gene. The 
presence / absence of a specific miRNA are directly proportional to 
changes in the levels of expression of Rluc. This vector provides a very 
significant advantage: it contains a Firefly luciferase (F-luc) gene which is 
constitutively expressed. Thus, there is no need of co-transfecting a control 
luc-gene (Figure 7B). 
 
Stable cell lines  
During the past years, many research groups have focused on 
developing more efficient high-throughput screening techniques in order to 
identify SMIRs. It has been proposed that using a stable cell line that 
constitutively expresses a luciferase reporter, (rather than a transient 
transfection), would be an approach more cost efficient and less time-
consuming. More so, it would eliminate variations associated with 
transfection efficiency and other technical manipulations. This approach 
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was tried by Connelly and colleagues; and in their study, they recorded the 
steps needed to create a stable cell line with a constitutively expressed 
vector [102]. In it they validated the Huh 7 cell line with a constitutive 
expression of psiCHECK2 vector with the miR-122 target sequence [102]. 
This technique could be applied to any other cell line as well as any other 
miRNA.  
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Figure 7: Examples of high-throughput screening (in vitro) techniques for SMIRs 
This figure is used with permission and originally published by Monroig, P., Chen, L., Zhang, S., and Calin, 
G. in 2015 in Advanced Drug Delivery Reviews 
(http://www.sciencedirect.com/science/article/pii/S0169409X14002002) 
 
(A) 
(B) 
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Hypothesis and Aims of the Study 
 
Even though miRNAs are small RNA molecules that do not codify for proteins, they 
can regulate their expression in a significant manner. Due to their mechanism of action, 
miRNAs have been demonstrated to be very important in contributing to the progress of 
diseases such as cancer. This has compelled the progress of drug development 
approaches such as the inhibition of oncogenic miRNA.  
 
MiRNA expression in BC has proven to induce tumor initiation, progression and 
metastasis. Death rates from BCs have decreased only slightly in the last decade, and 
new therapeutic approaches are under scrutiny. To identify new therapeutic targets for BC 
patients, we proposed to study oncogenic miRNAs that have been proven to target tumor 
suppressor proteins in BC (miR-9, miR-10b, miR-21, miR-155, miR-181a, and miR-181b). 
Among the miRNAs studied, two of them proved to be expressed at a significantly higher 
level compared to the others: miR-10b and miR-21. Thus, for this project, we envisioned 
the usage of small molecules to target and inhibit the function of these miRNAs.  
 
Screening for small molecules inhibitors of miRNAs represents enormous challenges 
Two of the most important ones are: (1) mature miRNAs are single stranded and 
unstructured, and (2) there are few high resolution structures of immature miRNAs. Thus, 
structure-based discovery is very difficult.  
 
Encouragingly, we studied the in vitro strategies employed in a handful of trials 
performed over the past few years (designed to identify small molecules inhibitors of 
miRNAs through different approaches). Herein we proposed to generate a high-
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throughput screening system, to screen for small molecule compounds that can directly 
interact and inhibit oncomir-10b / oncomiR-21.  
 
Overall hypothesis:  
Overexpressed oncogenic miRNAs can be inhibited by small molecules for BC 
treatment. The targeted inhibition will have biological consequences in cancer cells. 
 
We tested this hypothesis with the following specific aims: 
 
Aim 1: To identify oncogenic miRNAs with clinical relevance in breast cancer, and 
determine a strategy to screen for small molecule inhibitors that can target them. 
 
Aim 2: To perform a high-throughput screening, and determine positive hit candidates 
that can inhibit the identified oncogenic miRNAs. 
 
Aim 3: To determine the efficiency, potency and specificity of the small molecule inhibitors 
of the oncogenic miRNAs selected as targets; and to demonstrate the type of interaction 
between the molecule and the miRNA.   
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CHAPTER II: Methods 
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Integrative computational analysis and patient data selection. We performed a 
literature review and selected a group of 6 miRNAs that were validated to have tumor 
suppressor targets in breast cancer (through microRNA arrays, in vitro and in vivo models, 
and/or patient cohort studies) [47, 53, 58, 63, 64, 66, 69, 71, 110-138]. Then, we obtained 
clinical information and miRNA expression (miRSeq) from patients with invasive breast 
carcinoma (BRCA), from “the Cancer Genome Atlas Project” (TCGA) available through 
the associated files of the paper:  Comprehensive molecular portraits of human breast 
tumors, Nature, September 27, 2012 (https://tcgadata.nci.nih.gov/docs/ publications/) [3]. 
For these patients, we also downloaded their most recent clinical information from the 
TCGA portal (http://tcgadata.nci.nih.gov/). We merged the clinical information from both 
sources. All statistical analyses were performed in R (version 3.0.1). All tests were 2-sided 
and considered statistically significant at the 0.05 level.  
 
Kruskal-Wallis test was applied to assess the relationship among miRNA 
expression levels in tumors and a box-and-whisker plot was used to visualize the miRSeq 
data.  Further along, the Shapiro-Wilk test was applied to determine whether data followed 
a normal distribution.  The t-test or analysis of variance (depending on the number of 
groups considered) was applied to normally distributed data; otherwise the Mann-Whitney-
Wilcoxon test or again the Kruskal-Wallis test was applied to assess the relationship 
between miRNA expression levels and clinical parameters. A box-and-whisker plot (Box 
plot represents first (lower bound) and third (upper bound) quartiles, whiskers represent 
1.5 times the interquartile range) was used to visualize the miRSeq data.  
 
For each miRNA, we checked for a relation with the survival as follows.  Patients 
were grouped into percentiles according to the miRNA expression. The Log-rank test was 
employed to determine the association between miRNA expression and overall survival 
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and the Kaplan-Meier method was used to generate survival curves. Cut-off points to 
significantly split (log-rank test p-value <0.05) the samples into low/high miRNA groups 
were recorded. The cut-off to optimally separate the patients in high/low (min p-value) was 
chosen.  
 
Cell Culture.  Cell lines were obtained from the American Type Culture Collection 
and grown as suggested by the supplier.  Experiments were performed using The BC cells 
MCF-7 cultured in DMEM plus 10% FBS, and MDA-MB-231 and MDA-MB-468 cultured in 
RPMI. We also used 293FT cells which were grown in DMEM at 10% FBS. In addition we 
used MiaPaCa-2, Hey-A8, HepG2, and DLD1 cells corresponding to pancreatic cancer, 
ovarian cancer, hepatocellular carcinoma and colorectal cancer cells. The medias used 
were the same ones suggested by ATCC, at 10%FBS. All cells where maintained at 37◦ 
C in a humidified atmosphere of 5% CO2. 
 
miRNA correlation analysis. The Spearman's rank-order correlation test was 
applied to measure the strength of the association between miR-10b and miR-
21.  Statistical analysis and scatter plot graph were done using R (version 3.0.1) 
(http:///www.r-project.org/) and the statistical significance were defined as a p-value less 
0.05.  We imposed also a cut-off of functional relevance on the Spearman correlation 
coefficient in absolute value of 0.2 based on the method published previously [Integrated 
genomic analyses of ovarian carcinoma, Nature 474 (2011), pp 609-615, (Table S7.1)] 
[139]. 
 
Reporter Plasmid Construction.  To develop a high-throughput screening system 
for identifying microRNA inhibitors, we acquired the Psi-CHECK 2 luciferase reporter 
vector (Promega). We then designed and acquired complementary oligonucleotides 
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(Thermo Scientific) for hsa-miR-21 and hsa-miR-10b based on the mature miRNA 
sequences for both (Appendix - Table 2). In the design of the exact microRNA target 
sequence, we added several base pairs to have two different restriction sites recognizable 
by the enzyme SgfI at one side, and PmeI on the other (both of the restriction sites were 
present in the vector as well). In addition, the insert was designed with a restriction site for 
SacI enzyme in order to have an additional site to digest the vector when monitoring 
colonies for the presence/absence of the insert. 
 
The designed oligonucleotides were annealed as follows. Complementary strands 
were mixed at a 1:1 molar ratio in a microcentrifuge tube. The mixture was diluted to a 
fnial concentration of 1pmol/µl with a buffer solution of 10mM Tris, 1mM EDTA, 50mM 
NaCl (pH 8.0). The annealing reaction was prepared the same way for both miRNAs. In 
brief, the reaction consisted of 1ul of 100µM oligo#1, 1uL of 100µM of oligo#2, 5µL of 0.5M 
NaCl and 43µl of TE buffer. Both mixes were incubated at 95◦ C for 5 minutes, then the 
heat was reduced gradually for 70 minutes, until reaching 4◦ C. Subsequently the reaction 
was aliquoted and stored at -20◦ C.  
 
The annealed oligonucleotides were digested along with the Psi-CHECK2 vector 
with the enzymes were digested with SgfI and PmeI according to the manufacturer’s 
protocols for the enzymes (New England Biolabs/NEB). In brief, 1µg of DNA was digested 
with 1µl of each of the enzymes for 1 hour at 37◦ in a total reaction volume of 50µL. 
Digested products where purified with a DNA purification kit (Qiagen). Vector and inserts 
where ligated at the 3’-UTR (downstream) of the Renilla luciferase reporter gene in the 
psiCHECK-2, using T4 ligase and buffer (NEB), at a ratio of 1:40 vector: insert (to ensure 
insertion). Ligation was left for 2 hours at room temperature. Vector ligated without any 
insert (oligonucleotide sequence) was used as control. 
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Ligation reactions where transformed into One Shot Top 10 E. coli cells (Life 
Technologies). Cells where initially thawed on ice and 2.5 µl of ligation reaction was added 
to 25µl of competent cells and mixed gently by tapping. Mixes where then incubated on 
ice for 30 minutes. Then reactions where “heat shocked” for 30 seconds at 42◦ C, followed 
by a 2 minute incubation on ice. Subsequently, 250µl of SOC medium (at room 
temperature) was added to each and incubated for 1 hour at 37◦ C shaking (200rpm). Each 
reaction was then spread on pre-warmed plates with LB and ampicillin. Colonies were 
then selected, and grown in LB broth overnight at 37◦ C shaking (200rpm). Vector 
constructs were extracted from the bacteria using a mini-prep kit (Qiagen), according to 
the manufacturer’s protocol. Insert sequences were further confirmed two ways. Firstly, 
by enzymatic digestion (according to the manufacturer’s protocol - NEB), which was done 
with SacI, for the restriction site we designed in the insert and BamHI, for a restriction site 
contained in the vector (digestion with these two enzymes should theoretically give 2 
products of approximately 1600bp and 4600bp). Secondly, the sequences were confirmed 
by sequencing, with primer sequences described previously [140]. 
 
Sensitivity Assays for reporter vector constructs. A total of (2.0 x 104 MCF7- 
cells/well) were plated the evening prior to transfection and treatment with a final volume 
of media of 100µl. Cells where transfected with the psi-CHECK2 vector containing the 
miR-10b target sequence, either alone or in combination with pre-miR-10b, or 
antagomiR10b (acquired from Life Technologies). Concurrently, scramble sequences 
were used as controls. All transfections were performed in triplicates for statistical 
analysis. The exact protocol was used for miR-21 cloned vector as well. The final 
concentration of the vector transfected was 25ng/100µl (250ng/mL), while for the 
precursors and antagomiRs they were 50nm and 100nm respectively. Six hours after the 
transfection, media was completely removed and replaced with new one. After 48 hours 
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of incubation the media was removed, and cells were lysed and assayed with a Dual 
Luciferase Assay (Promega) was performed using a Vi-Tech luminometer. The ratio of 
Renilla to Firefly luciferase expression was calculated for each of the triplicates and the 
data was analyzed.   
 
Molecular Luciferase-Based Small Molecule Inhibitor Screening. An inhibitor 
screening library of lyophilized and dissolved in DMSO was purchased (Selleckchem 
Chemicals). Compounds from this company have been used in the past by different 
research groups [141, 142]. MCF-7 cells were seeded 24 hours prior to transfection, in 96 
well plates (2.0 x 104 cells/well).  All transfections were performed in triplicates for 
statistical analysis. The cells were incubated at 37◦ C for 6 hours, followed by replacement 
of the transfected media with fresh media containing the small molecule inhibitors to 
screen at a concentration of 10 µM each.  After 48 hours of incubation the media was 
removed, and cells were lysed and Dual Luciferase Assay (Promega) was performed 
using a Vi-Tech luminometer. The ratio of Renilla to Firefly luciferase expression was 
calculated for each of the triplicates and the data was analyzed. Results of the complete 
library after transfection with the luciferase construct and small molecule treatment were 
merged together in 2 groups (according to the targeted miRNA -10b or 21. The top 5% of 
compounds with the highest luciferase fold change were considered positive hits and 
further studied. 
 
RNA extraction.  The media was removed from the plates containing the cells.  
Cells were washed with PBS, and RNA was isolated using Trizol Reagent (Invitrogen).  
RNA extraction was performed according to manufacturer’s instructions. RNA quantity 
was assessed with NanoDrop ND-1000 (Thermo Fisher Scientific) and the integrity was 
analyzed by gel electrophoresis.  
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cDNA synthesis and quantitative real time PCR analysis.  Positive hits from the 
luciferase-based screening assay were selected to further confirm their potential as 
SMIR’s. Their inhibition was tested in MCF-7 cells at the same concentration and time 
point but through a different technique: RT-PCR.  Cells were seeded in 6 well plates the 
evening prior treatments at a confluency of 50-60%.  They were then treated with the small 
molecule compound hits, at a concentration of 10 µM and RNA was collected after 24 and 
48 hours. MicroRNA expression was tested using TaqMan microRNA assay (Applied 
Biosystems). The cDNA was synthesized using TaqMan Reverse Transcription Reagents 
kit (Applied Biosystems) and employed for quantitative RT-PCR analysis together with 
TaqMan probes and SsoFast Supermix (Bio-rad) according to the manufacturer’s protocol. 
Primers and probes were purchased for hsa-miR-10b, hsa-miR-21, hsa-pri-miRNA-10b 
and hsa-pri-21 and U6 snRNA (which was used as an internal control) (Appendix - Table 
3). Experiments were performed in triplicates; treated samples were compared to the 
DMSO solvent and normalized to the reference gene (snRNA U6) as an experimental 
control. Relative expression levels were calculated using the 2-ΔCt method by Michael W. 
Pfaffl [143]. 
 
To detect the levels of the precursor sequences, no commercial taqman probes 
are available. Thus,  cDNA was synthesized using the SuperScript III cDNA kit 
(Invitrogen), and diluted cDNA was used for RT-PCR analysis using iQ SYBR Green 
Supermix (Bio-Rad) with the appropriate primers (Table 4) according to the manufacturer’s 
protocol. Relative expression levels were calculated using the 2-ΔCt method by Michael W. 
Pfaffl [143]. 
Computational model of pre-mir-10b (third fragment) in complex with Linafinib.  
The secondary structure of pre-mir-10b (third fragment) was predicted by CentroidFold 
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[144, 145]. RNA tertiary structure was predicted by RNAComposer using the predicted 
secondary structure as the constraints [146]. Molecular docking was performed using 
rDock2006 [147, 148]. We explored the binding site using the geometrical center of 
UG:AGU internal loop as sphere center, 15Å radius, and RbtCavityGridSF site searching 
scoring function. A total of 200 separate runs were performed using rDock_solv scoring 
function. We selected the binding mode that received the best rDock_solv score for 
demonstration. 
 
Lentivector-based MicroRNA Precursor Constructs. Primers for the precursor 
sequences of each microRNA were designed (OligoPerfectTM Designer) including BamH1 
and Ecor1/Not1 restriction sites (Appendix- Table 4). The amplicon was subsequently 
confirmed by sequencing in the pCR2.1-Topo Vector (according to the manufacturer’s 
protocol). We then digested the pCDH-CMV-MCS-EF1-copGFP vector (System 
Biosciences), along with the vector containing our insert. Subsequently, we ligated and 
purified the construct already containing the precursor sequences of our interest with a kit 
for DNA purification (QIAGEN) according to the manufacturer’s protocol.  
 
For the lentiviral production, 293FT cells were grown in DMEM supplemented with 
10% FBS and “splitted” when they were 80% confluent. Cells were transfected in 10cm 
dishes when 60% confluent with 8.0µg of transfer vector (pMirna – System Biosciences), 
5.2µg of the packaging vector (CDH-CMV MCS-EF1-copGFP) and 2.8µg of the envelope 
vector (pMD.G – System biosciences). After 48 hours of incubation the supernatant 
containing the virus was collected and filtered (0.45 micrometers). MCF7 cells were then 
taken to infect with the virus supernatant, containing either the empty vector, or the vector 
containing sequences for pre-miR10b or -21. When 60% confluent, 2mL of viral 
supernatant was added to the cells, along with Polybrene/Sequabrene antibiotic, at a final 
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concentration of 8µg/mL. The plate was then centrifuged 1500-1800g for 90 minutes, and 
incubated at 37◦ C for 30 minutes. Finally the media was removed and replaced with fresh 
one. Transfection efficiency was monitored through GFP, as well as RT-PCR. 
 
Dose-Dependent Cell-based assays. The luciferase-reporter vector construct was 
used to test the half maximal effective concentration (EC50) at which each small molecule 
inhibitor induced a response halfway between the baseline and maximum after a specified 
exposure time. Cells were plated at a 50-60% confluence the evening prior transfection. 
Transfection was performed as initially done for the screening, and effectiveness of small 
molecule inhibitors was tested at three separate time-points 24 and 48 hours. A total of 5 
different concentrations were tested in serial dilutions and the EC-50 was determined for 
each compound using MCF7 cells. 
 
Cell Viability. Cell viability and IC50 were determined by the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide  (MTT assay). Briefly, 2.0 x 104 MCF7- 
cells/well were plated the evening prior to treatment in 96 well microculture plates. After 
cells were adherent, 5 different doses of the drugs were added to the supernatant. After 
24 and 48 hours, the MTT reagent (Sigma) was added to each well and incubated for 3 
hours at 37◦ C. The optical density (OD) was read at 570nm on a microplate 
spectrophotometer and growth values (%) were calculated as (OD treated cells / OD 
untreated cells) x 100. The experiments were performed in quadruplicates after 24 and 48 
hours. 
 
In vitro migration and invasion assay. For migration, 8 micron translucent inserts 
for 24 well plates were covered with gelatin (100µL) were put to gently shake/rotate for 2 
hours. Excess solution was discarded, and plates were left to dry under sterile conditions 
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for 1 hour. Following this, 50,000 cells were seeded onto the top of gelatin-coated insert 
and 500 μl of media with 10% FBS was added to the bottom of each well. Cells were left 
to migrate 24 hours.  The cells that migrated to the bottom of the well were fixed, stained 
(HEMA 3 stain set – according to manufacturer’s instructions), and counted using a 
microscope. For each well, 5 different fields were counted and the average number of 
cells was determined. The experiments were performed in triplicates. The same protocol 
was used for invasion assay with a top coat containing collagen and laminin. Results were 
normalized for proliferation 
 
Proliferation assay: Cell proliferation was determined using a colorimetric assay 
were the highly water-soluble tetrazolium salt WST-8 (Dojindo Molecular Technologies) is 
reduced by dehydrogenase activities in cells to give a yellow-color formazan dye, which 
is soluble in the tissue culture media. The amount of the formazan dye, (generated by the 
activities of dehydrogenases in cells, and directly proportional to the number of living cells) 
was measured after 3 hours of incubation. The OD was read at 450 nm on a microplate 
spectrophotometer and growth values (%) were calculated as (ODtreated cells 
/ODuntreated cells) x 100. The experiments were performed in triplicate. 
 
Statistical analysis The qRT-PCR, luciferase dosage dependent analysis, 
migration and invasion assays were performed in triplicates.  A (two-sided) t-test was 
applied to compare the mean between control and treated samples. Analyses were carried 
out in GraphPad (Prism 6). The statistical significance was defined as a p-value less 0.05. 
MTT assay: data and analysis The MTT experiments were performed in quadruplicates. 
A (two-sided) t-test was applied to compare the mean between solvent control and treated 
samples. Analyses were carried out in GraphPad (Prism 6).  The statistical significance 
was defined as a p-value less 0.05.    
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Nuclear Magnetic Resonance. The human microRNA sequences were obtained from 
miRBase database (http://www.mirbase.org/). RNA molecules were prepared by in vitro 
transcription using T7 RNA polymerase (approximately 2 ml reaction) using 15N isotope 
labeled 5'-NTPs (nucleoside triphosphates) and purified over PAGE gels using 
established procedures [149, 150]. Resonance assignments for the RNA hairpins 
containing the target motifs were be obtained using standard homonuclear and 
heteronuclear multidimensional NMR techniques (e.g. HCCH-TOCSY, HNN-COSY, and 
13C- or 15N-edited 3D NOESY-HMQC) [151]. Inter-proton distances were derived from 1H-
1H NOESY and 13C/15N-edited 3D NOE-based spectra. Residual dipolar couplings (RDC’s) 
were generated by Pf1 phage-induced weak alignment of the RNA molecules and 
incorporated into the structure determination [152-155]. Assignment of constraint values 
and the structure calculation protocols were similar to those in the following manuscripts 
[152, 155-157].  
 
Spectrums of the RNA and the DMSO (solvent) were used as controls. Peaks in the 
samples with the RNA and small molecules were compared to the control spectrums to 
predict miRNA-compound interactions. To confirm peak changes in any positive 2D NMR, 
we designed RNA Oligonucleotide sequences (Dharmacon) to create shorter segments 
of the primary transcript of miR-10b of approximately 50 base pairs (with some bases 
overlapping each other between sequences). We then read a 1D NMR spectrum to 
determine in a more precise way in which segment of the primary the molecule was 
binding to. 
Western Blot. Proteins were lysed with Lysis buffer (Cell Signalling Technology), 
diluted from 100X up to 1x, as well as phosphatase and protease inhibitors (also diluted 
from 100X to 1X). Cells were washed with PBS to remove residual medium. A total of 50 
– 100µl of cold 1x LB was added, and cells were mixed by pipetting. Subsequently cells 
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were incubated on ice for minimum 10 minutes with vortex every other minute during the 
time. Then lysate was centrifuged at maximum speed for 10 minutes at 4C. Supernatant 
where transferred to a new tube and stored at -80C until used.  
 
For protein quantification the equipment used was: Smartspec Plus 
Spactrophotometer (BioRad) and the BioRad Dye Reagent was used to dilute the proteins 
(1:1000). Criterion pre-casted gels (4-20% Tris-HCl 1.0mm) were used (BioRad), at a 
constant mAmp of 35 and a voltage of 160. “Trans-blot Turbo Transfer packs” were used 
to transfer the proteins to 0.2 µM nitrocellulose membranse, for a ten minutes (dry 
transfer). Membranes were blocked with 5% milk for one hour. Primary antibodies were 
left overnight, and secondary antibodies were left for 1-2 hours. 
   
Ingeuity Pathway Analysis (IPA). A detailed description of IPA can be found at 
http://www.Ingenuity.com. Genes of interest were entered into Path Designer using “My 
Pathway” function. Path Explorer tool was used to identify the shortest pathways among 
the genes using both Ingenuity pathway analysis knowledge base and external databases. 
Grow tool under “Build Tab” was also used to simultaneously explore direct or indirect 
relationships for either down-stream or up-stream molecules of the miRNA genes of 
interest.  
 
Identification of miRNA/mRNA target interactions /functional profiling. A large number 
of target prediction programs and databases on experimentally validated information have 
been developed for miRNAs.  For miR-10b and miR-21, we retrieved data on miRNA-
mRNA interaction predictions and miRNA-mRNA validated interactions from miRWalk 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).  miRWalk is a comprehensive 
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database on miRNAs, which hosts predicted miRNA-mRNA interactions (given by 8 
algorithms),  as well as validated miRNA-mRNA binding sites.  We also downloaded 
information on validated miRNA - target interactions from miRTarBase  
(http://mirtarbase.mbc.nctu.edu.tw/).  The data base miRTarBase accumulates miRNA-
target interactions (MTIs), which are collected by manually surveying literature (the 
collected MTIs are validated experimentally by reporter assay, western blot, or microarray 
experiments with overexpression or knockdown of miRNAs). For further analyses we 
chose mRNA targets predicted by at least 4 programs and/or validated by multiple assays. 
We used then KEGG Database Resource (http://www.genome.jp/kegg/) and PANTHER 
(http://pantherdb.org/) for a functional profiling of miRNA targets. 
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Evaluation of the clinical significance of validated oncomiRs in BC 
 
 
 
 Initially we carried out a literature review of recently validated oncomiRs in BC. The 
majority of the studies used where published within the last 5 years. We then selected a 
total of 6 microRNAs which were found to be highlighted as oncogenic in different BC 
studies in vitro / in vivo, and also in patient samples. These were: miR-9, miR-10b, miR-
21, miR-155, miR-181a and miR-181b. Following the selection of miRNAs, we carried out 
an integrative computational analysis to identify their clinical relevance within tumor 
samples from invasive BC patients. Using The Cancer Genome Atlas (TCGA) patient 
datasets of invasive breast carcinoma tumors, we found that miR-10b and miR-21 were 
overexpressed at statistically significant level when compared to all the others (both with 
a P<0.0001) (Figure 8). Thus, we selected these 2 oncomiRs for the purposes of our 
studies. 
  
 
 
 
 
 
 
 
 
Figure 8: Oncomirs -21 and -10b are highly expressed in invasive breast carcinoma 
tumors. 
Using TCGA patient data sets of all BC tumor types, a comparison between the levels of 
expression of miRs: -9, -10b, -21, -155, -181a, -181b, yield that miR-21 and miR-10b are 
expressed at a statistically significant higher level. 
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The expression of oncomiRs -10b and -21 are not correlated in BC patient 
samples. 
 
Within the TCGA patient dataset, we investigated if the levels of expression of both 
of these miRNAs were correlated. Initially we tested the complete datasate of invasive 
breast carcinoma tumors (n=590). Within the pooled set of samples, we found a correlation 
coefficient of -0.25; which, although negative, suggested statistical but not biological 
significance.  
 
We then separated the patient samples into 2 groups. As part of our first group, 
we selected patients with tumors types between stages I and II. In the second group we 
pulled together the patients with tumor between stages III and IV. Within these groups we 
did not find any correlation in the expression of miR-21 and miR-10b (Figure 9). We also 
divided patient samples by specific receptor status (ER, PR, TNBC), and found no 
significant correlation between the expression levels of both miRNAs (data not shown). 
Thus, we concluded their expression is not correlated in BC. 
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Figure 9: The expression of oncomirs -21 and -10b is not correlated in BC patients 
Using TCGA patient data sets of all BC tumor types, we investigated if the expression of 
miRNAs -21 and -10b was correlated.  Comparison between all the samples resulted in a 
small negative correlation (coefficient of -0.25). Although statistically significant these 
results did not suggest a significant biological correlation. More so, dividing the patients 
by specific tumor stages did not yield any correlation between the expression of miR-10b 
and -21. 
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Individual assessment of miR-10b/-21 levels of expression within specific BC 
tumor subtypes 
 
In order to better understand the significance of the miR-10b and miR-21 
overexpression in invasive breast carcinoma samples from patients (TCGA database), se 
grouped them according to their estrogen, progesterone and HER2 receptor status. We 
found a significant increase in the levels of expression of miR-10b, in ER+ subtypes 
compared to their negative counterparts (Figure 10A). Similarly, PR+ patient tumor 
samples had higher miR-10b levels compared to negative tumor types (Figure 10B). We 
further confirmed this tendency by studying samples from patients with TNBC tumors, and 
found that the levels of miR-10b were significantly lower in the group of patients with TNBC 
tumor types (compared to non-TNBC) (Figure 10C). We thus confirmed for the first time 
to our knowledge, that high levels of miR-10b are characteristic of ER+PR+ subtypes of 
breast cancer tumors. 
 
Within the same group of tumor samples (grouped by the expression of ER, PR 
and HER2), we analyzed the expression levels of miR-21. Interestingly there was no 
difference in the levels of miR-21 between ER/PR +/- tumor samples (Figure 11A and 
11B), nor so in TNBC or non-TNBC (Figure 11C). We thus confirmed, not only that miR-
21 is overexpressed in invasive breast carcinoma samples, but that its overexpression 
seems to be independent of the molecular classification of the tumor type (ER/PR/HER2). 
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Figure 10: Levels of expression of miRNA -10b within subgroups of BC patients 
classified by estrogen, progesterone and HER2 receptor status.  
 
 
(A) 
(B) 
(C) 
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Figure 11: Levels of expression of miRNA -21 within subgroups of BC patients 
classified by estrogen, progesterone and HER2 receptor status.  
(A) 
(B) 
(C) 
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Expression of miR-10b and miR -21 influence overall survival of ER+ BC patients 
 
 We determined to identify the influence of miR-10b and miR-21 overexpression in the 
overall survival (OS) of BC patients. Once again, using TCGA patient datasets, we 
analyzed the clinical correlation of the expression levels of miR-10b and miR-21 in 
different BC tumor subtypes. Our results demonstrated that miR-10b is associated with 
decreased OS, specifically in early tumor stages (I-II) of patients with ER+ tumor types 
(Figure 12A). Similarly, miR-21 overexpression correlated with OS in ER+ tumors; 
however, it was statistically significant only at later tumor stages (III-IV) (Figure 12B). 
Thus, we confirmed that both oncomirs are clinically relevant, but also, we identified a 
specific group of BC patients that could benefit from a miRNA-targeted therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: High levels of expression of miRNAs -10b and -21 correlate with 
decreased OS in BC patients.  
 
(A) High levels of expression of miR-10b are associated with decreased OS, of patients 
within early stages (I-II) of ER+ tumors. (B) Similarly, high levels of expression of miR-21 
also correlate with decreased OS in patients within tumor stages III-IV. 
 
(A) (B) 
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High-throughput screening of small molecule inhibitors targeting miR-10b/ miR-21   
 
With the aims of discovering novel therapeutic approaches for BC patients, we 
designed a step-wise approach to screen, detect and validate SMIRs targeting miR-10b 
or miR-21 through different assays (Figure 13).  
 
 
Figure 13: Screening Design 
 
Summary of the steps used to determine if small molecule inhibitors targeted miR10b/-21. 
The number of compounds remaining in the study after each step is shown.  
miR-10b miR-21 
Small Molecule  
Chemical Library of 
Compounds 
- HTS: Dual Luciferase biosensor assay 
- Confirmatory RT-qPCR: mature miRNA sequences 
- Validation: second cell line model 
- RT-qPCR: pri-miR and pre-miR  
- Nuclear magnetic resonance (NMR) 
- Efficiency and toxicity: Determination of IC50’s and EC50’s 
Functional Assays:  
     Migration/Invasion 
miRNA targeted-protein recovery:  
     Western Blot 
 
 
(481) 
(21) (19) 
(12) (3) 
- Specificity: Determination of levels of alternative oncomirs 
(3) 
(1) 
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Initially we constructed a reporter vector designed with complementary 
oligonucleotides for miR-10b, and another one for miR-21. We cloned these sequences 
on a psi-CHECK2 vector, downstream of a Renilla luciferase reporter gene (Figure 14A). 
We then tested the effectiveness of the cloning, by sequencing and also by verifying the 
presence of the insert in both of the vectors constructed. For the latter, we digested the 
vectors with SacI and BamH1 enzymes, for which restriction sites were present in the 
insert and vector (respectively). In the presence of the insert, the construct was cleaved 
at 2 sites (yielding 2 separate bands seen on agarose gels). On the other hand, if the 
vectors where empty (ligated upon themselves) only 1 band could be seen in the agarose 
gels (Figure 14B and 14C).  
 
Further along we tested the sensitivity of the reporter in detecting changes in the levels 
of expression of the miRNA for which they had the complementary target sequence. To 
do this, we transfected them into MCF-7 cells and alongside, we also added antagomiR-
10b/-21 or pre-miR10b/-21, to verify that the assay was sensitive in detecting the changes 
in their levels. In the presence of antagomiRs, luciferase expression increased 
significantly. On the other hand, in the presence of precursors, it decreased (when tested 
48 hours after transfection) (Figure 15A and 15B). Given the fact that the assay proved 
sensitive, we used it as the initial step of our screening (refer to Figure 13).  
 
Given the fact that miR-10a varies only by 1 in comparison with miR-10b, we also 
performed the sensitivity assay with antagomiRs and precursors for miR-10a for the psi-
CHECK2 vector containing the miR-10b target sequence. We found no statistically 
significant changes in luciferase expression when altering levels of miR-10a (Appendix-
Figure 38). Our results once again suggested sensitivity and specificity, only towards 
changies in miR-10b levels. 
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We screened a library of 450 small molecule inhibitors. A total of 6/96-well plates with 
scattered solvent controls were tested. The results of all six plates were merged, and are 
reported (Figure 15C). For results representing individual plates per compound, refer to 
the Appendix- Figures 39, 40 and 41. Compounds representing the top 5 % of compounds 
with the highest luciferase fold change expression were considered miR-10b small 
molecule inhibitor hits, and submitted to further testing. 
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Figure 14: Cloning of Psi-CHECK2 Luciferase vector constructs  
 
(A) Psi-CHECK-2 vector was used to clone the miR-10b / miR-21 target sequences 
downstream of a Renilla luciferase (Rluc) gene. After the transformation, vectors were 
extracted from E. coli colonies, and digested with SacI and BamHI enzymes to confirm the 
presence or absence of the insert. (B) Representative colonies from psi-CHECK2+ 
miR10b target sequence. (C) Representative colonies from psi-CHECK2+ miR21 target 
sequence. 
(A) 
(B) 
~ 4600 bp 
 ~ 1600 bp 
(C) 
~ 4600 bp 
 ~ 1600 bp 
Colony #:    1         2        3        4        5        6         7 
Colony #:    1      2     3      4      5     6      7      8      9      10  
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Figure 15: Luciferase-based microRNA biosensor assay detects changes in the 
expression levels of miR-10b and miR-21.  
 
(A and B) To test the sensitivity of the reporter vector construct, we transfected the vectors 
into MCF-7 cells, along with antagomirs/precursor sequences for miR-10b / miR-21. 
Luciferase expression increased significantly in the presence of antagomiRs, and 
decrease concurrently with the addition of precursor sequences. (C) Screening results of 
the acquired library revealed potential SMIR-10b/-21 candidates. Approximately 20 
compounds were selected from the top 5% with the highest luciferase expression. These 
were determined to be positive hits, and thus were chosen to perform confirmatory assays. 
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Validation of SMIR-10b and SMIR-21 candidates 
   
As a second step in our screening, we tested the positive hits from the luciferase-
based reporter assay with a technique that increased sensitivity: real time-quantitative 
polymerase chain reaction (RT-qPCR). MiR-10b / -21 inhibitions were evaluated by RT-
qPCR in MCF-7 cells at the same time point and under the same conditions at which the 
luciferase assay was performed (48 hours). Compounds confirmed as hits in the RT-PCR 
were considered “true positives”. Non-confirmed hits were considered “false-positives”, 
and therefore eliminated from our screening. In all, a total of 13 compounds were 
confirmed to decrease the levels of miR-10b, and 2 where confirmed to decrease miR-21 
(Figures 16A and 16B respectively). 
 
To further validate specific hits, we decided to verify whether the inhibition could also 
be achieved in one additional BC cell line model (MDA-MB-231 or MDA-MB-468, both 
triple negative). For this, we selected each of the validated hits, and repeated the exact 
same treatment conditions in one additional cell line, at two time points (24 and 48 hours). 
We observed that all the SMIR-10b and SMIR-21 validated hits inhibited miR-10b and 
miR-21 respectively in at least 1 additional cell line model under the same conditions 
(Figure 17 – Panels A, B and C). These results confirmed our previous findings in MCF-7 
cells, and demonstrated that the inhibition was not cell line-specific. 
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Figure 16: Validation of SMIR candidates using qRT-QPCR   
qRT-PCR was used as a confirmatory assay to increase the sensitivity of our screening 
results. We evaluated miR-10b/miR-21 inhibition in MCF-7 cells at the same time point at 
which the luciferase assay was performed (48 hours). Compounds confirmed to be 
positive hits in the RT-PCR were considered “true positives” (shown as  filled bar graphs). 
Non-confirmed hits were considered “false-positives” (shown as empty bar graphs). 
Several hit compounds belonged to the same family of inhibitors (shown as filled bar 
graphs with different patterns - per family type). 
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(NOTE: Panel B of this figure, as well as the figure legend appears on the 
following page.) 
D
M
S
O
2
4
 H
o
u
rs
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
****
D
M
S
O
2
4
 H
o
u
rs
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
****
D
M
S
O
2
4
 H
o
u
rs
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
**
****
D
M
S
O
2
4
 H
o
u
rs
 
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
**
D
M
S
O
2
4
 h
o
u
rs
 
4
8
 h
o
u
rs
 
0 .0
0 .5
1 .0
*
*
*
*
MDA-MB-468 MDA-MB-468 MDA-MB-231 
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
1-6D 3-2H 3-3H 
D
M
S
O
2
4
 H
o
u
rs
 
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
**
MDA-MB-231 
3-2G 
MDA-MB-231 
3-3G 
MDA-MB-231 
3-4G 
D
M
S
O
2
4
 H
o
u
rs
 
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
1 .5
***
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
-1
0
b
 l
e
v
e
ls
  
D
M
S
O
2
4
 H
o
u
rs
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
******
D
M
S
O
2
4
 H
o
u
rs
4
8
 H
o
u
rs
0 .0
0 .5
1 .0
1 .5
****
MDA-MB-231 
3-5G 
MDA-MB-231 
3-6G 
MDA-MB-231 
5-6A 
(A) 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: True positive SMIR compounds validated in TNBC cell lines (MDA-MB-
231 or MDA-MB-468). Panels A and B - All of the “true positive” SMIR-10b hits were 
treated at two time-points (24 and 48 hours), and all of them decreased miR-10b levels. 
The results were statistically significant when treated under the same conditions used in 
the initial screening assay. Panel C – The 2 “true positive” SMIR-21 hits were treated at 
two time-points (24 and 48 hours). They both decreased miR-10b levels, and the results 
were statistically significant after 24 and 48 hours of treatment. 
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Determining the specificity of oncomiR inhibition by SMIR candidates  
 
As the following step of our screening, we determined to identify possible off-target 
effect of the SMIRs, such as inhibiting other oncomiRs (not-10b / -21). For this, we used 
RNA from MCF-7 cells that had been previously treated with the SMIR hits (for both 
miRNAs). We then verified the levels of expression additional oncogenic miRNAs, to 
determine the specificity of the molecules (Figure 18A-F and Figure 19A-B respectively). 
We selected 4 oncogenic miRNAs from the group of 6 which we had initially found to have 
validated tumor suppressor targets in our literature review (-9, -155, -181a, -181b) [53, 
110, 111, 158]. For compounds of the same family (inhibitors of the same protein), we 
only tested 1-2 compounds, and the rationale behind this decision was that if compounds 
of the same family of inhibitors are decreasing the levels of miR-10b or -21, it is highly 
probable that the mechanism of action (mechanism of miRNA inhibition) is an indirect one 
(and not a direct one, which is the focus of our study). 
 
After verifying the levels other oncogenic miRNAs we divided the compounds into one 
of two groups: a “specific hits” group (defined as compounds that only altered the levels 
miR-10b, and not additional miRNAs), or “non-specific” group (defined as groups that 
decreased the levels additional miRNAs). The RT-PCR analysis of 4 oncomirs allowed the 
definition of a spectrum of specificity for each of the candidates. For example, compound 
6-11E from the family of HSP90 inhibitors was considered part of the group of “non-specific 
hits” (Figure 18E). On the other hand, compounds: 1-6D, 5-6A and 6-7C were considered 
“specific hits”, because treatment with them didn’t affect the levels of additional miRNAs 
tested (Figures 18A, 18B and 18C). 
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(NOTE: Panel D and E of this figure, as well as the figure legend appears on the 
following page.) 
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Figure 18: Levels of oncogenic  miRNAs (-9, -155, -181a, -181b) in BC cells treated 
with SMIR-10b compound hits. 
 
For SMIR-10b hit compounds, we tested the levels of expression of alternative oncomiRs 
after treatment with the SMIR-10b hits (A) 1-6D, (B) 5-6A, (C) 6-7C, (D) 3-3H and (E) 6-
11E, (F) 6-1F. 
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Figure 19: Levels of oncogenic  miRNAs (-9, -155, -181a, -181b) in BC cells treated 
with SMIR-21 compound hits. 
 
For SMIR-21 hit compounds, we tested the levels of expression of alternative oncomiRs 
after treatment with the SMIR-21 hits (A) 3-3G and (B) 4-6A. 
 
 
 
 
 
 
MCF-7 
4-6A 
m
iR
-9
m
iR
-1
5
5
m
iR
-1
8
1
a
m
iR
-1
8
1
b
0 .0
0 .5
1 .0
1 .5
* **
*
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
N
A
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
N
A
 l
e
v
e
ls
  
MDA-MB-231 
4-6A 
m
iR
-9
m
iR
-1
5
5
m
iR
-1
8
1
a
m
iR
-1
8
1
b
0 .0
0 .5
1 .0
**
**
* *
**
**
*
MDA-MB-231 
3-3G 
m
iR
-9
m
iR
-1
5
5
m
iR
-1
8
1
a
m
iR
-1
8
1
b
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
**
*
**
*
**
*
*
**
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
N
A
 l
e
v
e
ls
  
F
o
ld
 C
h
a
n
g
e
  
in
 m
iR
N
A
 l
e
v
e
ls
  
MCF-7 
3-3G 
m
iR
-9
m
iR
-1
5
5
m
iR
-1
8
1
a
m
iR
-1
8
1
b
0 .0
0 .5
1 .0
1 .5
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
(A) 
(B) 
71 
 
Non-specific hits reveal a role of Heat Shock Protein 90 in regulating miR-10b levels  
 
A total of 8 molecules, (out of the 13 confirmed miR-10b positive hits) belonged to the 
same type of family: inhibitors of heat-shock protein 90. Out of the 8 compounds, the RNA 
of 3 was tested to determine if the treatment also inhibited other oncogenic miRNAs in two 
different cell line models (Figures 18E, 18F). Since they also inhibited other miRNAs we 
grouped them in the “non-specifics” group of hits. Nevertheless, we observed that these, 
the inhibition of mIR-10b seemed to be strong, and the results were consistent among 
them. Thus, we selected the 2 most potent representatives from the family, 6-1F and 6-
11E to pursue further studies.  
 
For third time, we tested for miR-10b inhibition in MCF-7 cells after 24 and 48 hours of 
treatment (Figure 20 – left panel). More so, compound 6-1F decreased the levels of miR-
10b in MDA-MB231 after both: 24 and 48 hours of treatment, by approximately 65% and 
80% respectively (Figure 20 – bottom panel / right). Similar results were obtained with 
compound 6-11E decreased miR-10b levels after 24 and 48 hours of treatment by 25% 
and 50% respectively in an additional cell line tested (MDA-MB-231) (Figure 20 – bottom 
panel / left). Since the inhibition proved to be strong, we continued studying alongside, the 
role of HSP90 in regulating miR-10b in other cancer types.  
 
The 8 HSP90 inhibitors that formed part of our library had different chemical structures 
(Appendix Table 6). Furthermore, they were previously used in an array of clinical trials 
for different diseases such as cardiovascular disease, asthma, depression and cancer. 
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However, their most significant common feature is the protein they target: HSP90. We 
therefore hypothesized that indeed it was the inhibition of the HSP90 protein itself what 
was causing the down-regulation of miR-10b (rather than a direct interaction). To further 
explore the mechanism, we tested for the levels of the primary and precursor transcripts 
of miR-10b, to determine if the inhibition was achieved by targeting miR-10b biogenesis/ 
maturation. We found both the primary and precursor transcripts were also significantly 
decreased in MDA-MB-231 cells (Figure 21).   
 
We also investigated the possibility of validating our results in other cancer models in 
vitro. We thus tested 2 additional cancer types that have been recently linked to miR-10b, 
ovarian and pancreatic cancer [159-161]. We treated the ovarian and pancreatic cell lines 
HeyA8 and MiaPaca2 with two representative inhibitors of the HSP90 family. Our results 
demonstrated that miR-10b was inhibited in a time dependent manner at a standard dose 
of 10 µM (Figure 22). Thus, the miR-10b inhibition mediated by HSP90 inhibitors proved 
to be independent of the cancer type.  
 
Finally, using Ingenuity Pathway Analysis, (IPA), we predicted that HSP90 inhibitors 
could be regulating the transcription process of miR-10b, through the transcription factor 
TWIST (Figure 23). The validation of these predictions could result in future alternative 
pathways to target miR-10b. 
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Figure 20: HSP90 inhibitors decrease miR-10b levels in BC cells after both 24 and 
48 hours of treatment. 
 
The 2 compounds 6-1F and 6-11E (representative the HSP90 inhibitor family), decreased 
the levels of miR-10b after two different time-points of treatment: 24 and 48 hours. The 
results were consistent in both: MCF-7 and MDA-MB-231 cells. 
 
 
 
 
 
 
 
 
 
 
Figure 21: HSP90 inhibitors decrease the levels of expression of all three miR-10b 
transcripts: primary, precursor and mature sequence 
 
Treatment with compounds 6-1F and 6-11E for 24 hours decreased the levels of pri-miR-
10b, pre-miR-10b and miR-10b in MDA-MB-231 cells. 
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Figure 22: HSP90 inhibitors decrease the levels of miR-10b in vitro in pancreatic 
and ovarian cancer cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Ingenuity Pathway predictions of HSP90 regulating miR-10b transcription 
Dosage dependence and MTT assays reveal the inhibitory potency of the “specific 
hits”, as well as their half maximal inhibitory concentration of cell death 
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Three of the compounds were confirmed as “positive-specific hits” in our screening: 1-
6D-Bosutinib, 6-7C-Clomifene Citrate and 5-6A-Linifanib.  For all of them we determined 
the potency of the miR-10b inhibition by performing a dosage dependence assay. Using 
the previously cloned psiCHECK2 vector, we tested five different concentrations (ranging 
from .1µM – 50µM), at two different time-points (24 and 48 hours). Two of the compounds 
1-6D-Bosutinib and 6-7C-Clomifene Citrate, increased the luciferase expression 3 to 4 
fold after 48 hours of incubation at concentrations as low as .1 and 1µM (Figure 24A and 
24C). For both we determined the IC50’s after 24 hours, and 48 hours of treatment with 
the compounds in MCF-7 cells: 15.74µM, 8.3µM for compound 1-6D, and 15.2µM, 13.5µM 
for compound 6-7C respectively (Figure A and 25C). Similarly, we tested compound 5-6A 
and calculated the IC50’s in MCF7 cells, which were 42µM after 24 hours and 9.3µM after 
48 hours (Figure 24B). Moreover, compound 5-6A-Linifanib increased the luciferase 
expression from 6-fold, at 24 hours, to up to 10-fold, after 48 hours of incubation at a 
standard dose of 10µM (Figure 25B).  
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Figure 24: Dosage Dependence Assay 
The three compounds from the group designated “specific hits” for miR-10b, were tested 
for a dosage dependence assay in MCF-7 cells. A total of 5 concentrations were used 
(ranging from .1 - 50 uM). The assay was performed at two different time-points: 24 and 
48 hours. (A) SMIR 1-6D, (B) SMIR 5-6A and (C) SMIR 6-7C. 
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Figure 25: Determination of IC50’s of “specific hits” through MTT Assay 
Half maximal inhibitory concentration (for death) was calculated for all three compounds 
constituting the “non-specific group”. Experiments were done in MCF-7 cells at 24 and 48 
hour time-points. (A) SMIR 1-6D, (B) SMIR 5-6A and (C) SMIR 6-7C. 
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Nuclear magnetic resonance (NMR) analysis suggests small molecules 5-6A / 
Linifanib directly binds to miR-10b 
 
We proceeded next to determine if the top 3 compounds were validated to target miR-
10b using NMR. An RNA hairpin corresponding to pre-miR-10b was synthesized to screen 
for the RNA binding activity of the compounds by monitoring NMR chemical shift 
displacement and resonance broadening in the imino (NH) region of the RNA spectrum. 
Peaks in the NH region arise from base pairing and other stable base-mediated intra-
molecular hydrogen bond interactions. DMSO at 11% was used as a co-solvent for the 
compounds and was determined to have minimal effect on the NMR spectra. Although the 
size of the RNA molecule and the presence of non-canonical features in the stem of pre-
miR-10b limited the resolution of even the two-dimensional NH spectrum, no spectral 
changes could be observed for compounds 1-6D-Bosutinib and 6-7C-Clomifene Citrate 
(data not shown). However, compound 5-6A-Linifanib was found to cause small but 
reproducible chemical shift changes for peaks in the spectrum, suggesting a specific 
interaction between the molecule and the immature miRNA (Figure 26).  
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Figure 26: 2D NMR of pre-miR-10b and SMIR 5-6A / Linifanib  
(A) Precursor sequence of miR-10b used for in vitro transcription. (B) 2D-NMR spectrum 
of pre-miR-10b RNA (synthesized in vitro) in 10% DMSO. This spectrum was the control. 
(C) 2D-NMR spectrum of pre-miR-10b RNA and SMIR 5-6A / Linifanib. Changes in the 
spectrum are pointed out in the arrows. 
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In order to narrow down the possible site(s) of interaction and to reduce spectral 
complexity, the stem of the pre-miR-10b RNA molecule was divided into three overlapping 
segments of approximately 50-58 nt each (designated I, II and III) (Figure 27) and 
analyzed individually (for a detailed description of the designed models, refer to Appendix- 
Figure 42). A UUCG tetraloop was used to terminate stem segments I and II and the 
UCCG tetraloop native to pre-miR-10b was used to terminate stem segment III. The NH 
(1D) spectra of stem segments I and II, which correspond to the base and central regions 
of the pre-miR-10b hairpin stem, respectively, were unchanged after addition of 5-6A-
Linifanib, indicating the compound lacks affinity for these segments (data not shown). 
Peaks in the imino and downfield amino regions of the NMR spectrum of stem segment 
III, however, are altered by the presence of 5-6A, indicative of binding (Figure 29 – spectra 
on the left). Additional peak changes are observed in the base (C6H6/C8H8) region of the 
2D 13C-1H HSQC (Heteronuclear Single Quantum Coherence) spectrum (Figure 28). The 
regions of sequence overlap between stem segments II and III and the peak perturbations 
in the NH and base spectra indicate that binding occurs near the loop end of the RNA 
molecule, which is adjacent to nucleotides that are part of the mature 5p and 3p forms of 
miR-10b (refer to Figure 27- RNA III).  
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Figure 27: Design of oligonucleotide segments of pre-miR-10b 
The nucleotide sequence of the pre-miR-10b (miRbase.org), along with the designed 
oligonucleotide sequences accounting for three separate regions of the precursor 
sequence (as indicated by the selected regions as RNAI, II and III.  
 
 
 
 
 
 
 
 
Figure 28: 2D-NMR spectrum of RNA III and 5-6A / Linifanib 
Base regions of the 13C-1H HSQC spectra of RNA hairpin III in the absence (upper) and 
presence (lower) of 0.05 mM Linifanib/5-6A. The broad appearance of the peaks in the 
spectra is indicative of the dynamic nature of the molecule. 
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To further assess the specificity of this interaction, we designed a double mutant of 
the stem segment III:  U50C, A62C. These substitutions extend the Watson-Crick 
secondary structure to the base of the UCCG tetraloop region. The 1D NH spectrum of 
this variant is unchanged by the addition of up to 65 µM 5-6A-Linifanib, indicating that the 
compound no longer binds the stem segment III (Figure 29- specta on the right). Overall, 
these experiments support a direct interaction between 5-6A-Linifanib with pre-miR-10b 
that localizes to the (UG/UGA) internal loop proximal to the cleavage site of Dicer. 
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Figure 29: NMR (1D) with RNA segment III of the pre-mIR10b designed 
oligonucleotide 
 
The detailed structures of RNAIII is presented (top left panel), with the base paris where 
the molecule interacts with it exalted (green circle). The muted version of RNAIIII is 
presented (top right panel), with the mutated based paris exalted (green circle). Imino 1H 
spectra of stem segment III RNA hairpin in the absence (upper) and presence (lower) of 
0.05 mM Linifanib/5-6A. Some of the peaks whose chemical shifts or intensities are altered 
are indicated.  Imino 1H spectra of a double mutant of the stem segment III RNA hairpin 
in the absence (upper) and presence (lower) of 0.05 mM Linifanib/5-6A. The spectra 
display no differences indicating Linifanib/5-6A does not interact with the mutant RNA 
molecule. 
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Computational model of the stem loop region of pre-miR-10b in complex with  5-6A/ 
Linafinib  
 
With the known chemical structure of compound Linifanib/5-6a (Figure 30A), and a 
confirmed interaction to the stem loop region of miR-10b (through NMR), we generated 
an in silico model of Linifanib in complex with the UG:AGU internal loop (in stem segment 
III) using molecular docking. Figure 30B depicts the possible binding mode for 5-6A within 
the stem loop region of pre-miR-10b. Due to the non-canonical base pairing between G51 
and G63, the loop region was predicted to bend ~30° with respect to the stem, and A62 
formed a bulge which created an extra pocket for the urea phenyl group to bind. The 3-
amino-indazol moiety, moreover, formed aromatic stacking with G51 base and the amine 
group interacted with U61 base through hydrogen bonding. Recognition of this unique 
conformation of UG:AGU internal loop is consistent with extended Watson-Crick pairing 
and loss of Linifanib binding in the U50C, A62C double mutant. 
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Figure 30: Predicted molecular docking model of 5-6A / Linifanib and miR-10b 
(A Chemical Structure of Linifanib/5-6A. (B) Computational model of the stem loop region 
of pre-miR-10b in complex with Linafinib (using rDock). The majority of RNA-small 
molecule interactions occurs around UG:AGU internal loop, consistent to NMR data. 
 
(A) 
(B) 
86 
 
Linifanib /(5-6A) binds to the precursor sequence of miR-10b and inhibit its 
maturation process in vitro 
 
To strengthen the biophysically detected interaction between Linifanib/(5-6A) and 
pre-miR-10b, we tested the levels of expression of pri-, pre-, and miR-10b mature form, in 
the RNA of Linifanib/(5-6A)-treated MCF7-cells. Indeed we found that the levels of the 
primary transcript were increased 2-3 fold in the cell model tested. However, the levels of 
mature miR-10b decreased significantly. When testing for the pre-miR-10b sequences, 
we were not able to detect it in our RNA samples by qRT-PCR (Figure 31).  
 
 
 
 
 
 
 
 
 
 Figure 31: Assesment of levels of expression of pri-, pre- and mature-miR-10b 
transcripts 
MCF7 cells treated with linifanib/5-6A reduce the levels of mature miR-10b sequences (as 
tested by qRT-PCR), but increase the levels of its primary transcripts. Pre-miR-10b 
sequences were undetectable by this method. These results suggest an interruption of the 
miR-10b maturation process. 
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Treatment with Linifanib/(5-6A) recovers levels of expression of HOXD10 by 
targeting miR-10b without affecting miRNA biogenesis 
 
Additionally, cells were treated with Linifanib, and after 48 hours we verified the 
levels of the miR-10b targeted tumor suppressor protein HOXD10. Our results 
demonstrated a significant recovery of the HOXD10 levels (Figure 32A). Under the same 
conditions we tested for the levels of the two most important proteins required for miRNA 
biogenesis and maturation: Dicer and Drosha. With our experiments we demonstrated 
that treatment with Linifanib did not reduce the levels of any of these, suggesting miRNA 
biogenesis is not significantly altered (Figure 32B). 
 
 
 
 
 
 
 
 
Figure 32: Assessment of protein levels after Linifanib treatment (10uM) in MCF7 
cells. 
 
(A) Linifanib treatment in MDA-MB-231 cells recovers tumor suppressor target HOXD10. 
(B) At 10 µM dosage, Linifanib does not decrease the levels of Dicer, nor Drosha. 
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Linifanib/(5-6A) decreases miR-10b levels in MCF7 overexpressing clones 
 
 
We evaluated the potency of Linifanib in inhibiting the miR-10b in MCF7 clones 
overexpressing the precursor sequence of the miRNA. Once again we found that Linifanib 
was able to significantly decrease the levels of miR-10b, in conditions where the miRNA 
was overexpressed with a fold change of over 1000X. 
 
 
 
 
 
 
 
 
 
 
Figure 33: MCF7-miR-10b overexpressing clones 
 
MCF7 cells were transfected with a vector containing a constitutively expressed promoter 
(labeled pmiR). Downstream of the promoter we cloned the DNA sequence codifying for 
pre-mIR-10b. An empty vector was transfected as a control. (A) Transfection efficiency 
was monitored through GFP. (B) To test the empty vector vs. pmiR-10b, we extracted 
RNA from the cells transfected with both, and performed qRT-PCR for miR-10b levels.  
(C) Linifanib treatment after 24 hours reduced miR-10b levels in MCF-7-miR-10b 
overexpressing clones.  
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Linifanib /(5-6A) binds to the precursor sequence of miR-10b and inhibit its 
oncogenic functions in vitro 
 
We also tested for a reversal in the tumor-like phenotype that has been correlated by 
overexpression of miR-10b. BC cells with high basal levels of miR-10b were used to 
perform a wound healing assay. Alongside we compared Linifanib treatment with 
antagomiR-10b. Upon treatment with Linifanib/(5-6A) migration was reduced compared to 
solvent/DMSO, and the reduction was comparable to antagomiR-10b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Wound healing assay demonstrates that Linifanib decreases migration  
 
In MDA-MB-231 cells, treatment with Linifanib/(5-6A) reduced the migration capabilities 
(top panel). The inhibition of migration was comparable to cells transfected with 
antagomiR-10b (bottom panel). 
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Mir-10b has been demonstrated to affect migration and invasion. Nevertheless it has 
not been associated with influencing proliferation. Thus, we tested the effect of 
Linifanib/(5-6A) on proliferation in BC cells. We found that Linifanib strongly affects 
proliferation at approximately 63% after 24 hours of treatment. We assumed this 
mechanism was independent of the miR-10b inhibition, and for further functional assays 
where it was relevant, we normalized for proliferation. 
 
 
 
 
 
 
 
 
Figure 35: Linifanib inhibits proliferation in breast cancer cells 
MDA-MB-231 cells treated with Linifanib/(5-6A) reduced their proliferation in 63% after 
24 hours. 
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We then proceed to perform migration and invasion assay in BC cells with inserts 
coated with either gelatin or collagen. Cells treated with Linifanib markedly inhibited 
migration as well as invasion in BC cells. Our results were normalized for proliferation (by 
subtracting the 63% of the effect in cells treated with Linifanib), and still both (migration 
and invasion) were reduced significantly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Linifanib/(5-6A) treatment decreases migration and invasion in BC cells 
 
Linifanib/(5-6A) treatment decreases migration and invasion in MDA-MB-231 cells after 
24 hours of treatment. 
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Linifanib decreases miR-10b levels in hepatocellular and colorectal cancer cells in 
vitro 
 
We hypothesized that the inhibition of mIR-10b would be consistent among different 
cancer cell lines. In this regard, we opted to test cell lines of lung, liver and colorectal 
cancers. We selected these cancer types in particular because Linifanib was used in 
clinical trials for all of them. After a 24 hour treatment, we observed that the reduction in 
miR-10b levels was consistent among different cancer types such as: non-small cell lung 
cancer (NSCLC), HCC, and CRC (Figure 33).  
 
 
 
 
 
 
 
 
Figure 37: Linifanib decreases miR-10b levels in HCC and CRC cells in vitro 
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CHAPTER IV: Discussion 
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Summary 
 
Breast cancer is the second most common cancer in the world (following lung 
cancer), and the leading cause of cancer death in women [162]. Its burden exceeds all 
other cancers and the incidence rates are consistently increasing [163]. One of the main 
reason for this is the fact that the heterogeneity of BC tumors makes them a challenging 
one to treat [164].  
 
Regarding their molecular characterization, hormonal therapy has improved the 
outcome of patients with ER/PR positive tumors [165]. Herceptin has also significantly 
influenced treatment response and overall survival in patients with HER2 positive tumors 
[166]. However, taken together, these parameters have not achieved the realization of an 
extremely effective individualized targeted therapy for patients, and resistance to therapy 
continues to be frequently encountered in the clinic [12, 167, 168]. Furthermore, molecular 
subtypes such as TNBC tumors are not efficiently treated with the approaches above 
mentioned, and the prognosis of these patients is significantly low [169, 170]. Hence, new 
systemic therapies are desperately needed, and the study and development of 
personalized cancer therapy, represents a strategic approach in aiming to overcome 
therapeutic inefficiency and/or resistance [171].  
 
MiRNAs are a type of non-coding RNA transcript that can regulate oncogenic 
processes, and thus, they are considered crucial elements in fields such as: “personalized 
cancer therapeutics”. MiRNAs-based research throughout the years has emphasized that 
specific miRNAs are up- or down-regulated, concurrently, in cancer [73]. Their 
dysregulation, results in the activation/inactivation of oncogenes or tumor suppressor 
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genes respectively [73]. Therefore, from a therapeutic point of view, miRNA targeting 
possesses anti-cancer potential, based on the fact that the cancer phenotype can be 
changed by targeting miRNA expression. Furthermore, miRNA signatures and profiles in 
BC have been thoroughly studied in the past, and strong evidence has already been 
established regarding their therapeutic potential [3, 172, 173]. In this regard, the 
development of a therapy to target specific oncogenic mIRNAs represents a significantly 
important approach for new treatment options. 
 
In this study, we decided to focus on testing small molecules that have undergone 
clinical trials or that are already FDA approved (with adequate pharmacokinetic/dynamic 
properties for in-human delivery), to target microRNAs. We hypothesized that already-
available small molecules could bind specific RNA motifs and inhibit the function of 
oncogenic miRNAs. If proven effective, this would expand their applicability in the clinic, 
greatly accelerating the lengthy process of drug discovery [100]. In our approach, we 
combined techniques such as bioinformatics, non-coding RNA technologies, chemical 
compound library screening and structural chemistry, with the aim of identifying oncogenic 
miRNAs to target in BC. We also designed and validated a step-wise approach that can 
be used to discover small molecule compounds that directly bind oncogenic miRNAs and 
inhibit their functions in vitro.  
 
The key finding from this study is that Linifanib, the receptor tyrosine kinase 
inhibitor, directly interacts with the precursor sequence of miR-10b (a known oncogenic 
miRNA in BC). More so, we found that the interaction of Linifanib with the miRNA results 
in the recovery of tumor suppressor proteins (e.g. HOXD10) and can reverse the cancer 
phenotype in vitro. 
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Overall, we have identified a number of assays with high sensitivity and specificity, 
which allow an adequate identification of molecules that can target oncomiRs. Our 
techniques are reproducible and applicable to a broad range of other types of cancer, or 
to any other pathology that involves miRNA overexpression.  
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Small molecule compounds targeting miRNAs  
 
Compared to the currently known treatment regimens, miRNA-based therapeutics 
offers the advantage of targeting multiple genes with different roles within a cancer 
network. Previous strategies have involved the use of oligonucleotides or viral-based 
constructs; however, early clinical trials have showed that their delivery can be ineffective 
or toxic [100]. Recent focus regarding miRNA-based therapeutics has centered on the 
possibility of using small molecule inhibitors to target miRNAs directly. Nevertheless, to 
date, very few studies have successfully been able to find small molecules to target 
oncomirs in an effective manner. Herein we review the most important findings regarding 
small molecule compounds targeting miRNAs. 
 
The first screening assay to detect small molecules targeting miRNA processing 
was done by Davies and colleagues in 2006. Using pre-let-7 RNA from Drosophila 
melanogaster, they developed a doubly-labeled pre-miRNA beacon with a fluorescent 
emitter and quencher able to detect Dicer processing (hydrolysis) through fluorescence 
emission. In this way, they established the first homogeneous fluorescence assay to 
detect miRNA inhibitors [106, 107]. However, their main focus was to find molecules that 
targeted the miRNA biogenesis process (in a non-specific way). 
In 2008, a study done by Gumireddy and colleagues; the group claimed to have 
found an inhibitor of a miRNA [104]. They selected miR-21 as the target miRNA because 
of its known tumorigenic properties in cancer [38, 69, 174, 175]. They then developed a 
lentiviral reporter construct with the miR-21 target sequence, downstream of a luciferase 
reporter gene. Diazobenzene, was found as positive hit in the study; however a thorough 
analysis revealed that the compound actually targeted the transcription of the miR21-
coding gene [104]. In another similar study,  Young and colleagues developed a project 
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focused on targeting miR-122, a miRNA crucial for hepatitis C virus (HCV) infection and 
replication [176]. A luciferase based psiCHECK-2 reporter plasmid was used to screen for 
SMIRs [176], and 2 hits were identified. Nevertheless, both of the compounds targeted the 
transcription of the miRNA-coding gene upon treatment (againproving to have an indirect 
mechanism of inhibition) [176].  
 
Following this, Watashi and colleagues developed a very extensive screening for 
SMIRs that could target oncomiRs -93 and -130b [177]. Collectively their results 
suggested that one of their compounds reduced pre-miRNA association with Dicer, while 
the other reduced the miRNA association with AGO2 (enzymes important for miRNA 
biogenesis) [90,[177] . Even though both treatments demonstrated to reverse the cancer 
phenotype in vitro, their mechanisms of action were indirect ones [177]. In a similar 
approach, Bose et.al; screened for SMIRs against miR-21, using a luciferase-based 
reporter was used (pEZXMT01 plasmid) with the complementary 3’UTR sequence [108]. 
In the screening, Streptomycin was found as a hit inhibitor in a BC model in vitro, by 
interfering with the Dicer processing of the miRNA [108]. However, when testing the levels 
of additional miRNAs to determine the specificity of the inhibition, out of a total of 10 tested, 
miR-27a was proven to be downregulated as well [108].  
 
The idea of targeting miRNAs with small moelcules continued expanding in 2013 
when Bose and colleagues used a fluorescent probe (Refer to Figure 7A) to screen a total 
of 14 compounds, and test if any of them inhibited miR-27a, a miRNA proven to be over-
expressed in several cancer types [103]. They found that a set of them inhibited Dicer-
catalyzed miR-27a maturation [103]. Their high-throughput beacon-based assay 
compared favorably to other previously described methods, as it proved to be cost-
effective, sensitive and robust. Unfortunately their results were validated in vitro only in 1 
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cell model (which doesn’t rule out that the compound-mediated inhibition is cell-specific 
manner) 
 
With the aims of achieving SMIR against miR-21 with a higher specificity, Shi and 
colleagues designed an in silico technique [101]. By using the three-dimensional structure 
of the Dicer binding site on the pre-miR-21, they conducted an in silico screening of 1990 
compounds to find molecules that could block miR-21 maturation using MC-Fold/MC-Sym 
and Auto Dock programs [101]. Through this method, they identified a SMIR termed 
AC1MMYR2, which blocked the ability of Dicer to process the pre-miR-21. Its potency was 
tested and validated in vitro [101]. More so, the compound demonstrated a decrease in 
tumor growth, invasiveness, and metastasis, thereby increasing overall host survival in 
vivo [101]. Their approach was very successful in the fact that they actually managed to 
thoroughly evidence a reversal of the cancer phenotype. Nevertheless, 5/11 alternative 
miRNAs tested, were also significantly reduced upon treatment [101]. More so, they did 
not perform assays to demonstrate a direct interaction between the structure of the 
molecule and the pre-miR-21. 
  
On another note, two important miRNAs in gastric cancer: miR-372 and miR-373, 
were also the focus of investigation when searching for SMIR candidates. In their 
screening, Vo and colleagues reported the first example of multimodal RNA ligands aiming 
to inhibit the biogenesis of oncomiRs [178]. The multimodal ligands were composed of an 
artificial nucleobase design  that recognizes the pre-miRNA, and an aminoglycoside 
known to interact in a potent manner with stem-loop RNAs (with high affinity) [178]. Some 
of their multimodal ligands inhibited Dicer precursor cleavage by binding to these stem-
loop structured RNAs [178]. More so, one of their hits proved to be an efficient miR-372 
and -373 inhibitor in vitro, demonstrating a dose dependent decrease of the miRNAs [178]. 
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Their approach demonstrated to be successful for targeting these particular oncomiRs; 
however, they identified a significant decrease in the levels of at least 3 other oncogenic 
miRNAs as well, upon treatment. 
 
Recently, a research group developed “Inforna”, a novel approach that was 
validated to design lead compunds that target miRNA precursors previously identified 
through sequencing and functional studies [179]. Initially they downloaded the sequences 
of all the miRNA hairpin precursors in the human transcriptome, and subsequently, their 
secondary structures were predicted in silico. Inforna created the output of the targetable 
motifs in each RNA, and the corresponding lead small molecules that could potentially 
bind them [179]. Their results showed a strong interaction between benzimidazole and the 
precursor sequence for miR-96 [179].  Unfortunately these results were only validated in 
vitro in a single cell line model. 
 
Finally, Murata and colleagues studied the synthesis and structure–activity 
relationships of xanthone and thioxanthone derivatives as fluorescent indicators of 
interactions between small molecules and RNA sequences [180]. In their study they 
demonstrated that the xanthone and thioxanthone derivative X2S-N, N-diMe inhibited 
premiR-29a maturation in a specific manner by binding to the nucleotides that form part 
of the internal loop/bulge (but not by any interaction with the processing enzyme Dicer) 
[180]. However, the off target effect of this compound (inhibition of other miRNAs) was not 
investigated [180].  
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Current challenges 
Compared to proteins, miRNAs (and all RNA molecules in general) have been 
quite neglected as promising drug targets. This is mostly due to the absence of defined 
molecular structures for the majority miRNAs; a fact that increases the difficulty of 
predicting which inhibitors can bind them. However, the truth of the matter is that miRNAs 
are indeed “druggable”, due to the formation of stem loop in precursor sequences and 
bulges in miRNAs [88]. Their structural features not only enlarge the major groove for drug 
entry, but also partially disclose the internal bases, scattering the local electronegative 
distribution [88]. These advantages suggest that it would be feasible to target them with 
small molecules.  
Only a handful of studies have been published over the last 10 years, regarding 
small molecules targeting miRNAs. Although advancements in screening techniques and 
validation of targeted hits have been seen, there are still weaknesses in the studies 
performed, and thus several challenges to overcome. In view of this, we aimed to identify 
the most important ones, to determine what changes could be implemented when 
screening for SMIRs. Altogether, our primary endpoint was to find drugs that could be 
specific by targeting oncomiRs directly; and as the initial step when doing so, we 
determined to address several flaws (which will briefly be discussed). 
 Firstly, we determined that it is important to test if our compounds cause any 
alterations of the miRNA biogenesis pathway machinery. The reason for this is because 
when the concept of targeting miRNAs with small molecules began, one of the ideas was 
targeting their maturation process in cells; and several research groups performed 
screenings focusing on finding inhibitors of the miRNA biogenesis pathway. However, this 
approach proved inefficient, due to the fact that by inhibiting miRNA 
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biogenesis/maturation, the expression of all miRNAs was targeted / affected. MiRNAs 
crucial for cellular homeostasis could be altered in this manner, not to mention many tumor 
suppressor miRNAs would be affected as well. Thus, we determined it was crucial to test 
if the small molecule treatments have an effect in elements (such as enzymes like Dicer, 
Drosha) that are required for the processing of miRNAs (their maturation process).  
Secondly, but on the same line, we believe that it is very important to determine if 
treatment with the small molecules affects the transcription of the miRNA-coding gene (of 
our miRNA of interest). This could be done by testing changes in methylation of promoter 
sequences of the specific miRNA-coding gene; or more easily, by verifying the levels of 
primary and precursor sequences (along with the mature miRNA itself). The later because 
when small molecules target transcription, the levels of all three miRNA transcripts are 
decreased upon treatment.  
On a separate note (thirdly), the levels of additional miRNAs should be tested 
under the same conditions done in which the screenings are performed. Unfortunately in 
several of the studies done to date, the levels of additional miRNAs were not tested after 
treatment, a fact that doesn’t allow a “prediction” of the degrees of specificity of the 
inhibition. More so, those that claim to do so “randomly” select miRNAs to test in addition 
to their target one, but their selections include miRNAs that are not considered oncogenic, 
or that have even been validated to be tumor suppressors (not oncomiRs that might have 
similar functions in cancer). Additionally (fourthly), in vitro models should include at least 
two different cell lines with different properties, in order to demonstrate that the small 
molecule inhibition is not cell-specific, but miRNA-specific. 
Finally (fifthly), one of the most significant weaknesses of the SMIR studies to date 
is that none of them have demonstrated enough evidence describing a direct interaction 
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between a small molecule and the miRNA of interest. The closest to it, was when a 
research group demonstrated through an in silico-predicted docking model, that the small 
molecule AC1MMYR2 bound to the pre-miR-21 and blocked its maturation [101]. 
However, their models were not validated through techniques such as nuclear magnetic 
resonance or mass spectroscopy; and thus there is a level of uncertainty regarding the 
interaction itself. This uncertainty arises due to the fact that miRNAs (the majority) are not 
available as a crystal structure, and thus the 3D computerized models actually use a 
prediction of their crystal structure when searching for candidates molecules that can 
target them. In other words, they are actually developing a model that is based on: “a 
prediction of a prediction”. Because of this, very few molecules identified through 
computerized programs as:  “likely to bind a specific miRNA”, have an actual interaction 
that is able to be validated in vitro an in vivo. From this perspective, the biggest challenge 
is not quite to find a compound that evidently inhibits an oncogenic miRNA, but more so 
proving that it does so through a direct interaction.  
To this extent, we believe that a specific SMIR:miRNA interaction could be thoroughly 
evidenced by addressing all of the mentioned criteria. In summary, these criteria include 
proving that the small molecule does not alter the following: miRNA biogenesis 
/processing, the levels of expression of additional oncogenic miRNAs, or the transcription 
of the specific miRNA-coding gene. To achieve an even more precise SMIR:miRNA 
interaction, results should be validated in at least two cellular models (with different 
characteristics. Additionally, it is crucial to demonstrate a direct interaction through 
structural analysis such as crystallography or nuclear magnetic resonance. 
Small molecule screening for SMIRs targeting miR-10b or miR-21 
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Chemical compound libraries offer the advantage of allowing screenings of known 
therapeutic agents, the majority of which have been tested in pre-clinical and clinical trials, 
some even approved by the FDA for different diseases. As a result of screening libraries 
of chemical compounds, new potent inhibitors have been discovered for and array of 
diseases such as infections, neurological disorders and cancer [181-183]. In this study, 
as proof of concept, we used approximately 450 compounds from a chemical library of 
known small molecule inhibitors to test their ability to interact with, and inhibit oncomir-10b 
or -21. The results of our screening demonstrated that using a combination of assays with 
high specificity and sensitivity, we were able to find a small molecule that directly interacts 
with, and inhibits an oncogenic miRNA (miR-10b).   
 
Role of heat shock protein 90 in regulating the transcription of miR-10b 
As part of our screening design, we performed a series of assays to test if the small 
molecules where specific on their miRNA inhibition. As a result, we eliminated compounds 
that altered the levels of expression of any of the oncogenic miRNAs tested after treatment 
(besides the targeted one). Interestingly we found a group of compounds belonging to the 
same family of inhibitors: inhibitors of heat-shock protein 90. Even though these inhibitors 
proved to downregulate two or more miRNAs in a non-specific manner, they demonstrated 
to inhibit miR-10b very potently (even though they had very different molecular structures). 
More so, they demonstrated to decrease the levels of all three: primary, precursor and 
mature miR-10b transcript. 
With the aims of establishing a link between HSP-90 inhibitors and decrease in 
miR-10b levels, we used Ingenuity Pathway Analysis, (IPA), to predict the correlation 
between HSP90 inhibitors and miR-10b. In our prediction we found that HSP90 enhances 
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the activity of HIF1-alpha, which promotes both TGFB4 and STAT3. Furthermore, TGFB4 
and STAT3 were both predicted to enhance TWIST, a transcription factor known to 
increase the expression of miR-10b (Figure 23).  
In the past, several studies had already proven to link several of these 
relationships, although (to our knowledge), no one has validated the complete pathway 
from HSP90 to miR-10b. For example, for years a direct correlation between HSP90 
protein and HIF1-alpha has been known. A research group in 1999, demonstrated 
thoroughly for the first time, that Hsp90 activity is essential for HIF-1 activation, by 
demonstrating that using the HSP90 inhibitor geldanamycin, they achieved potent 
inhibition of HIF-1alpha [184]. Since then, several research groups have validated the 
interaction between both proteins extensively [185, 186].  
Regarding elements further down the pathway, it has been demonstrated that 
TGFβ triggers SMAD-dependent induction of 2 important transcription factors: SNAIL1 
and TWIST [187]. Additionally, several studies have indicated that STAT3 transcriptionally 
induces Twist, which plays an important role in promoting migration, invasion, and 
anchorage-independent growth [188, 189]. Finally, the transcription factor TWIST has 
been thoroughly demonstrated to increase the transcription of miR-10b, which is also 
predicted in our IPA model (refer to Figure 23) [63, 64] . 
Unfortunately, from the correlations of our IPA-predicted pathway there have not been any 
studies that validate hif1-alpha as a regulator of TGB4 or STAT3. Interestingly STAT3 has 
indeed been validated to regulate HIF1alpha expression [190, 191]. Thus, the majority of 
the predictions from the IPA model have been individually proven in the past; which 
strongly suggest the pathway has a high probability of being validated altogether. The 
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confirmation of these predictions could lead to alternative pathways to target in diseases 
where miR-10b is an overexpressed miRNA contributing to pathology. 
 
Small molecule Linifanib targets miR-10b through a direct interaction 
In our screening, we identified 5-6A-Linifanib as a specific SMIR which blocks miR-
10b processing by binding to the precursor sequence near the stem loop region. More so, 
we validated the direct interaction thoroughly using NMR techniques to assess the 
molecular dynamics of the small molecule in the presence of pre-miR-10b. 
 
Previous studies 
Linifanib is a novel potent inhibitor with selectivity for the VEGFR and PDGFR 
family of receptor tyrosine kinases (RTKs) [63, 64, 192]. In nonclinical in vivo studies, 
Linifanib demonstrated potent inhibition of tumor growth in xenograft models of over 15 
different tumor types [75]. In preclinical studies, it was also proven to have antitumor 
activity as a single agent or in combination with known chemotherapies [77] . To date, 
Linifanib has proven to be clinically active in patients with an acceptable safety profile; 
therefore, a total of 18 clinical trials have been initiated in diseases including solid tumors 
such as BC [193], CRC, non-small cell lung cancer (NSCLC) [194], renal cell carcinoma 
(RCC) [195], but to a more significant extent in HCC [77]. Specifically, in a phase 1 clinical 
trial, it demonstrated potent antitumor effects as a single-agent in patients with refractory 
solid malignancies [196]. More so, Linifanib has also shown antitumor activity in phase 2 
studies in patients with NSCLC, HCC or RCC [194, 195].  
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The most significant studies in which Linifanib has been used as a therapeutic 
agent have been performed in HCC. Remarkable results have been achieved (several 
years ago) in both: nonclinical, and preclinical trials; and thus, it became evident that 
linifanib could be considered a potential new threatment for patients HCC [75, 77]. In order 
to do so, linifanib was compared with the standard of care treatment for patients with HCC: 
the multitargeted tyrosine kinase inhibitor sorafenib, which blocks the activity of Raf 
serine/threonine kinase isoforms, VEGFR-2 and -3, PDGFR β, c-KIT, FLT-3, and RET. By 
doing so, sorafenib inhibits tumor angiogenesis and cell proliferation [26, 27, 197-201]. It 
was chosen as standard of care for patients with advanced HCC based on results from 2 
large randomized trials, both which showed an improvement in overall survival (OS) 
compared to placebo [200].  
 
In order to compare their efficiencies, both inhibitors were compared in (2014), in 
a randomized phase 3 trial in patients with advanced HCC [200]. The primary endpoint of 
the trial was comparing OS between treatments of linifanib vs. sorafenib. The results of 
the trial demonstrated that there was a slight difference in the median OS of patients 
treated with Linifanib vs Sorafenib, of 9.1 months and 9.8 months respectively [200]. 
However these results were not statistically significant. More so, regarding the secondary 
outpoints of the study: the time to progression (TTP) of patients receiving linifanib were 
significantly longer (P=.001), and the objective response rate (ORR) of these patients was 
also significantly higher (P=0.018) [200]. Furthermore the response rates (RR) for linifanib 
compared favorably to previous phase 3 trials of sorafenib in advanced HCC (13% vs 
6.9%) [198, 199]. Nevertheless, improvements in all these did not translate into increase 
in OS. Thus, the study failed to achieve its primary endpoint, and sorafenib continues to 
be the treatment of choice for these patients. 
108 
 
New mechanistic role of Linifanib 
In our screening we observed and validated a new mechanistic role for Linifanib: 
the direct inhibition of miR-10b. In BC models we observed that Linifanib decreased the 
levels of miR-10b, and the sensitivity of the inhibition was consistent among three different 
cell line models, suggesting that the effect was independent of the molecular 
markers/histological tumor subtypes. By restoring the levels of the tumor suppressor target 
HOXD10, Linifanib decreased invasion and migration of BC cells. Since previous studies 
have demonstrated both in vitro and in vivo, that silencing of miR-10b markedly 
suppresses formation of BC metastasis [47, 63], linifanib represents an attractive agent to 
target BC disease progression (and spread) by inhibiting, the “oncmiR-10b addiction” of 
these tumor types. 
The fact that linifanib physically interacts with, and inhibits miR-10b, opens up a window 
of therapeutic opportunities, not only for BC, but for other cancer types as well. As 
previously described, linifanib treatment has been tested (and is currently being tested) in 
several clinical trials, of cancer types such including CRC, NSCLC and HCC. Interestingly, 
all of these cancer types have been proven to worsen upon increased miR-10b 
expression. For example, high level miR-10b expression was found to be significantly 
associated with high incidence of lymphatic invasion and poor prognosis in CRC patients 
and has been shown to confer resistance to chemotherapeutic agents in vitro [202]. 
Furthermore, in NSCLC miR-10b expression levels are significantly positively correlated 
with the tumor stage and regional lymph node involvement, and patients with higher levels 
of miR-10b have significantly poorer survival compared to those with lower expression of 
this miRNA [203, 204]. More importantly, miR-10b is highly expressed in metastatic HCC 
tissues inducing invasion and migration; and patients with higher miR-10b expression 
have significantly poorer OS [137, 205].  
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The evidence of miR-10b having a crucial role in cancer types for which linifanib 
has been explored as a possible treatment option, suggests that there might be a link 
between overexpression of miR-10b and linifanib treatment inefficiency. Supporting this 
are the results of the phase 3 randomized clinical trial evaluating linifanib treatment in 
patients with advanced HCC. Results demonstrate that initially (first 3/4s of the treatment 
period) linifanib proofs more effective than the standard of care (with a higher progression 
free probability) compared to the standard treatment (sorafenib). Additionally, OS seems 
to be equal between both treatments during the initial 3/4s of the treatment period, and 
only separates from the standard-of-care treatment at the very end of the treatment period. 
These results, alongside the fact that miR-10b expression increases upon metastatic HCC 
and is associated with decreased OS, suggest that high levels of miR-10b can overcome 
the “miR-10b targeting” by linifanib and contribute to disease progression/relapse. Thus, 
in clnical trials of patients with advance HCC, where linifanib did not impove the OS 
compared to Sorafenib, we speculate that poor responders to linifanib are most likely 
patients with enhanced miR-10b overexpression to begin with, or developed along a 
period post-treatment to overcome the effect of linifanib. 
In this regard, we believe that the fact that Linifanib inhibits miR-10b (along with its known 
targets), could be contributing to define the therapeutic efficacy of preclinical models and 
clinical trials of different cancer types, and that the combination of linifanib with additional 
agents could increase the positive outcomes of cancer patients. To achieve this (and as 
a subsequent translational approach of our findings), we believe that by evaluating the 
chemical functional groups of Linifanib that target motifs of the pre-miR-10b, we will have 
a basis to develop a series of small molecules with variable levels of affinity towards RTKs, 
and more towards binding miR-10b. We predict that SMIRs against miR-10b could offer 
potential therapeutic benefits in additional tumor types that have been proven to be 
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oncomiR-10b addictive, not only breast but also, HCC,  NSCLC, CRC, pancreatic cancer 
and glioblastoma [160, 161, 206]. Furthermore, our study validates the fact that by 
upscaling screenings such as this one to a high throughput manner, many potential SMIRs 
could be discovered and used as targeted therapy for cancer patients. 
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CHAPTER V: Future Directions 
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Structure analysis of small molecule inhibitors of miRNA (SMIRs) maturation  
 
MiRNA precursor sequences have array of internal loops and non-canonical pairings 
in combinations that are unique for each miRNA, offering target specificity. However, 
structural based hit discovery highly relies on precise high-resolution structures, and with 
miRNAs, their inherent flexibility limits the number of structures available (approximately 
1% in Protein Data Bank). Only a handful of structures have been elucidated for miRNA 
fragments and none of them are in complex with small molecules. Furthermore, in silico 
modeling techniques for RNAs have not yet reached the capacity of those for protein 
targets. Limitations on direct structure determination and computational modeling have 
significantly restricted drug discovery efforts against RNAs.  
 
One of the approaches to overcome these challenges and barriers is developing an 
integrated platform for miRNA structural studies and inhibitor discovery by combining 
cutting-edge in silico modeling and direct structure methodologies. Dedicated 
computational methods are in the need of being employed, in order to build initial structure 
models of miRNAs. Validation of these methods through solution NMR is critical in order 
to investigate their conformational dynamics, and generate an ensemble of structures that 
accurately reflect their conformational distributions. 
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 Medicinal synthesis and testing of newly synthesized compounds to establish 
structure-activity relationship and drive lead optimization  
 
Derived knowledge from miRNA structural studies can be used to design new more 
potent derivatives. Each of the scaffolds can be synthesized followed by experimental 
evaluations for biological activity in vitro and in vivo. The process of lead optimization 
would most definitely be a synergistic and iterative process involving modeling, synthesis, 
and biological testing.  
 
To complement the optimization of linifanib (5-6A) (or other prospective compounds), 
a structure-based strategy can be implemented in order to identify compounds specific for 
non-Watson-Crick features in the stem of pre-miR-10b (Figure 26C). Heteronuclear NMR 
spectroscopy can be used to generate ensembles of structures that accurately reflect the 
conformational distribution sampled by the centrally located C-A and A-A mismatches and 
the GUAA/AAAC internal loop at the base of the hairpin. RNAs I and II (Figure 27) , which 
contain these features, can be used. These data could serve as the input for structure-
based virtual HTS hit identification and alternative SMIR design.  
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In vivo studies to characterize optimized lead compounds 
 
Expanding the pharmacokinetic (PK) experiments would be an important path to 
continue directing this project. Studies including absorption and distribution of the 
administered drug, as well as the rate at which a drug action begins, the duration of the 
effects, the chemical changes of the substance in the body (e.g., by enzymes), and the 
effects and routes of excretion of the metabolites of the drug are significantly important. 
PK studies should be done using only rodent at single, multiple, or cassette dosing. They 
should include preclinical non-compartmental pharmacokinetics, compartmental 
pharmacokinetics, ascending dose (assessment of dose proportionality), repeat dose 
(assessment of multiple-dose linearity), etc.  
 
The toxicity of the modified compounds should also be assessed through gross 
observation, blood chemistry, and selected tissues taken for histological examination. 
Concentrations should be determined through techniques such as high performance liquid 
chromatography. The plasma area under the concentration time curve of the molecules 
should be determined, as well as other pharmacokinetic parameters, including half-life 
(T1/2), apparent volume of distribution (Vd), clearance (Clint), etc. 
 
Drug physicochemical properties are critical for their stability, formulation, 
bioavailability, and other pharmacokinetic behavior. Several pharmacodynamic properties 
are also important to be studied to determine the gastrointestinal absorption and the 
compound’s oral bioavailability [207]. Lipophilicity, is also a key determinant of the 
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pharmacokinetic behavior of drugs that should also be assessed , as well as the 
compound’s chemical stability [208]. 
 
 Completion of PK and pharmacodynamic studies, would clearly lead to assessing the 
anti-tumor activity of lead compounds in vivo independently and in combination with either 
anti-miR10b, LNAs or with standard chemotherapy regimens. The main objective of such 
studies would be to investigate in vivo antitumor activity of our lead compound against 
breast tumor xenografts in scid mice. The primary endpoint of the experiments would be 
overall survival (OS), defined as the time from the malignant cells administration to the 
time of death or to the time of sacrifice. By targeting overexpressed miR-10b with a specific 
SMIR, we expect that apoptosis will be induced, and more so, invasion and migration will 
be reduced. We believe that altogether the anti-tumor activity will be significant in animal 
studies. 
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Table 2: Oligonucleotide design for Psi-CHECK2 vector inserts 
 
 
      miRNA / Mature sequence                  Designed oligonucleotides    
        # 1 5' - CGCAGTAGAGCTCTAGTCACAA     
               hsa-miR-10b          ATTCGGTTCTACAGGGTAGTTT - 3' 
          
 
UACCCUGUAGAACCGAAUUUGUG # 2 5' - AAACTACCCTGTAGAACCGAATT 
            TGTGACTAGAGCTCTACTGCGAT - 3   
        # 1 5' - CGCAGTAGAGCTCTAGTTCAAC      
                hsa-miR-21           ATCAGTCTGATAAGCTAGTTT - 3'   
              
  UAGCUUAUCAGACUGAUGUUGA # 2 5' - AAACTAGCTTATCAGACTGATGT  
                TGAACTAGAGCTCTACTGCGAT - 3'   
 
 
Nomenclature: 5’ SgfI site – linker – miR-10b binding site – PmeI site– 3’ 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Taqman Real-Time PCR Assays 
 
miRBase ID Assay Name Assay ID Catalogue # 
hsa-miR-10b-5p hsa-miR-10b 002218 4427975 
hsa-miR-21-5p hsa-miR-21 00397 4427975 
n/a U6 snRNA 001973 4427975 
miRBase ID  Stem loop accession # Assay ID Catalogue # 
hsa-miR-10b MI0000267 Hs03302879_pri 4427012 
hsa-miR-21 MI0000077 Hs03302625_pri 4427012 
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Table 4: Primers designed for this study 
 
 
Primer 
name: 
Type: Sequence: Experiment: 
pre-miR-10b Forward CCCTGTAGAACCGAATTTGTG RT-PCR of premiR 
sequence 
pre-miR-10b Reverse TGAAGTTTTTGCATCGACCA RT-PCR of premiR 
sequence 
pre-miR-21 Forward TGTCGGGTAGCTTATCAGAC RT-PCR of premiR 
sequence 
pre-miR-21 Reverse TGTCAGACAGCCCATCGACT RT-PCR of premiR 
sequence 
U6-
normalizer 
Forward CTCGCTTCGGCAGCACA RT-PCR reference 
gene (control) 
U6-
normalizer 
Reverse AACGCTTCACGAATTTGCGT RT-PCR reference 
gene (control) 
pre-miR-10b Forward CGGGATCCTCCTTGGGATGGA Clone-premiR-DNA 
coding region 
pre-miR-10b Reverse CGGGATCCAGGAAAAGCTGCT Clone-premiR-DNA 
coding region 
pre-miR-21 Forward CGGGATCCGTTTTTGATTGAA Clone-premiR-DNA 
coding region 
pre-miR-21 Reverse CGGGATCCTTTATTTGTGGTC Clone-premiR-DNA 
coding region 
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Table 5: Antibodies 
 
Antibody Name Manufacturer Catalogue ID 
Vinculin Santa Cruz sc-7649 
HOXD10 Abcam ab90704 
Dicer Cell Signaling 
Technologies 
5325 
Drosha Cell Signaling 
Technologies 
3364S 
α-Tubulin Sigma Aldrich T9026 
 
 
 
 
 
Table 6: Molecular Structures of the Heat Shock protein-90 inhibitors included in 
the study 
 
 
120 
 
 
 
 
 
 
 
 
 
 
Figure 38: Luciferase-based reporter for miR-10b levels tested in the presence of 
different levels of miR-10a 
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Figure 39: Luciferase-based screening for miR10b:  Plates 1-6. 
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Figure 40: Luciferase-based screening for miR21: Plates 1-6. 
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Figure 41: Luciferase-based screening for miR21: Plates with excluded outliers. 
 
 
 
 
 
 
 
 
 
 
 
 
Plate 1 
Plate 3 
Small Molecules 
 (Columns represent groups of 8 molecules) 
Small Molecules 
 (Columns represent groups of 8 molecules) 
F
o
ld
 C
h
a
n
g
e
 R
e
n
il
la
/F
ir
e
fl
y
 
F
o
ld
 C
h
a
n
g
e
 R
e
n
il
la
/F
ir
e
fl
y
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plate 5 
F
o
ld
 C
h
a
n
g
e
 R
e
n
il
la
/F
ir
e
fl
y
 
Small Molecules 
 (Columns represent groups of 8 molecules) 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Detailed design of oligonucleotide sequences for NMR studies. 
 
 
The nucleotide sequence of the pre-miR-10b (miRbase.org). Three guanine nucleotides 
were added to the 5’ end to facilitate in vitro transcription. The mature 5p and 3p miR-10b 
sequences (capitalized and italicized) are released after processing by Dicer. Boxed 
regions show segments of the stem that were prepared as three separate RNA hairpins. 
Helical segments I (dotted) and II (dashed) were capped by UUCG tetraloop sequence to 
facilitate folding of the RNA molecules. The UCCG loop sequence of segment III (solid) 
was left unchanged. Cross-strand pairing in the terminal loop exends the helix and 
introduces an internal loop (UG/UGA). 
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